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Abstract
Metastasis represents one of the most devastating aspects of cancer. Epithelial to mesen-
chymal transition (EMT) has been shown to play a critical role in tumorigenic metastasis. 
During metastatic progression, both genetic and epigenetic modifications endow cancer 
cells with properties that modulate the capacity for metastatic success. Histone modifica-
tion is profoundly altered in cancer cells and contributes to cancer metastasis by con-
trolling different metastatic phenotypes. Here, we first review histone modifications and 
discuss their roles in EMT and metastasis, with a particular focus on histone methylation 
and acetylation. Second, we review the major histone modification enzymes that control 
chromatin in cancer metastasis. Third, we discuss the transcriptional regulation concerted 
by these enzymes with EMT transcription factors at different molecular layers. Finally, 
we discuss pharmacologic manipulation of histone modification enzymes for metastasis 
treatment. A comprehensive understanding of histone modification in metastasis will 
not only provide new insights into our knowledge of cancer progression and metastasis, 
but also offer a novel approach for the development of innovative therapeutic strategies.
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1. Introduction
Approximately 90% of cancer deaths are caused by metastasis [1]. Cancer metastasis is an 
exceedingly complex process involving tumor cell motility, intravasation, and circulation 
in the blood or lymph system, extravasation, and growth in new tissues and organs [2, 3]. 
During invasion, tumor cells lose cell–cell adhesion, gain mobility and leave the site of the 
primary tumor to invade adjacent tissues. In intravasation, tumor cells penetrate through the 
endothelial barrier and enter the systemic circulation through blood and lymphatic vessels. In 
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extravasation, cells that survive the anchorage-independent growth conditions in the blood-
stream attach to vessels at distant sites and leave the bloodstream. Finally, in metastatic colo-
nization, tumor cells form macrometastases in the new host environment [2, 3]. All of these 
steps, from initial breakdown of tissue structure, through increased invasiveness, and ulti-
mately distribution and colonization throughout the body, are developmental characteristics 
of the processes, epithelial to mesenchymal transition (EMT) and mesenchymal to epithelial 
transition (MET). EMT is a distinctive morphogenic process that occurs during embryonic 
development, chronic degeneration and fibrosis of organs, and tumor invasion and metastasis 
[4–6]. The similarity of genetic controls and biochemical mechanisms that underlie the acqui-
sition of an invasive phenotype and the subsequent systemic spread of cancer cells highlights 
the concept that tumor cells usurp this developmental pathway for metastatic dissemination. 
In total, EMT provides tumor cells with the proclivity for early metastasis, renders them resis-
tance to therapeutics and endows cells with cancer stem cell (CSC)-like traits [6].
The hallmark of EMT is the loss of E-cadherin expression, an important caretaker of the epi-
thelial phenotype. Loss of E-cadherin expression is often correlated with the tumor grade 
and stage because it results in the disruption of the cell–cell adhesion and an increase in 
the nuclear β-catenin. Several transcription factors have been implicated in the regulation 
of EMT, including the zinc finger proteins of the SNAIL family (SNAIL1/2/3), the basic 
helix–loop–helix (HLH) factor TWIST (TWIST1/2, E12/E47), and two double zinc finger and 
homeodomain ZEB family (ZEB1/ZEB2). These factors act as a molecular switch for the EMT 
program by repressing a subset of common genes that encode cadherins, claudins, integrins, 
mucins, plakophilin, occludin and ZO1, and thereby induce EMT.
EMT is a dynamic process that preserves plasticity [6]. In this instance, the reprogramming 
of gene expression provides a rapid and dynamic regulatory mechanism to switch between 
the epithelial and mesenchymal conditions during cancer progression. Consistent with this, 
these EMT-activating transcriptional factors (EMT-TFs) are liable proteins that turn over rap-
idly and do not have long residence times at their binding sites. Interestingly, disseminating 
cells orchestrate a metastatic cascade without a concomitant need for genomic mutations, 
which indicates that this dissemination is epigenetically templated. Both EMT and epigenetic 
modification (DNA methylation and histone modifications) are dynamic and efficient pro-
cesses during development, differentiation and carcinogenesis. These studies indicate that 
the epigenetic mechanism plays an important role in modulating the induction of EMT and 
tumor metastasis.
2. Epigenetics and histone modification
2.1. Epigenetic and chromatin structure
The term “epigenetics” was first coined by Conrad H. Waddington in his Principles of 
Embryology textbook in 1942 to designate a process in which gene regulation modulated 
development. The final definition of epigenetics was confirmed in the Epigenetic Meeting 
held by the Banbury Conference Center and Cold Spring Harbor Laboratory in 2008 as “a 
stably heritable phenotype resulting from changes in a chromosome without alterations in 
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the DNA sequence.” In general, epigenetic regulation includes changes that impact histone 
modification, DNA methylation, histone variants, chromatin looping, noncoding RNAs and 
nucleosomal occupancy and remodeling.
Genomic DNA is tightly packaged in chromatin by both histone and nonhistone proteins in the 
nucleus of eukaryotic cells. The basic chromatin subunits, nucleosomes, are formed by wrap-
ping 146 base pairs (bp) of DNA around an octamer of four core histones: H2A, H2B, H3, and 
H4. Whereas the nucleosomal core is compact, eight flexible lysine-rich histone tails protrude 
from the nucleosome that modulate internucleosomal contacts and provide binding sites for 
nonhistone proteins. From the perspective of gene transcription, chromatin structure can be 
divided into two distinct categories: euchromatin and heterochromatin. “Euchromatin” is an 
open chromatin structure that affords accessibility of transcription factors to DNA, resulting 
in gene activation. In contrast, “heterochromatin” is a closed chromatin structure with a low 
interaction between transcription factors and the genome, leading to gene repression.
2.2. Histone modifications and histone code hypothesis
The histone code hypothesis was first proposed by Strahl and Allis in 2000. They suggested 
that “multiple histone modifications, acting in a combinatorial or sequential fashion on one 
or multiple histone tails, specify unique downstream functions” [7]. The histone “language,” 
based on this “histone code,” is encoded in these modifications and read by chromatin-associ-
ated proteins. So far, several histone post-translational modifications (PTMs) have been identi-
fied, including acetylation, methylation, phosphorylation, ubiquitination, sumoylation, ADP 
ribosylation, proline isomerization, biotinylation, citrullination and their various combinations 
[8]. These modifications constitute a unique “code” to regulate histone interactions with other 
proteins and thereby allow modification (either overcoming or solidifying) of the intrinsic his-
tone barrier to transcription. Accordingly, with these modifications, the various proteins that 
add, recognize and remove these PTMs, termed writers, readers and erasers, respectively, have 
been identified and structurally characterized. While “writer” and “eraser” enzymes modify 
histones by catalyzing the addition and removal of histone PTMs, respectively; “reader” pro-
teins recognize these modified histones and ‘translate’ the PTMs by executing distinct cellular 
programs. In addition, numerous core histone chaperones also facilitate core histone deposi-
tion or removal from chromatin. Histone modifications control dynamic transitions between 
transcriptionally active or silent chromatin states, and regulate the transcription of genetic 
information encoded in DNA (the “genetic code”) [9]. Analyses of genome-wide profiles of 
histone modifications and gene expression identified three distinct types of configurations: 
repressed, active and bivalent. First, the closed chromatin configuration is linked with sup-
pression of gene transcription, the repressed state. Second, an open chromatin configuration is 
associated with active gene transcription, the active state. Third, bivalent chromatin consists of 
domains that have both repressive and active histone markers, predominately on developmen-
tal genes, which allows phenotypic plasticity before committing to a specific cell fate.
During EMT, histone modifications provide a regulatory platform to orchestrate the repres-
sion or activation between epithelial and mesenchymal genes. Here, we only focus on the 
well-studied histone acetylation and methylation, and discuss their diverse regulation and 
role in transcriptional reprogramming of tumor metastasis (Table 1).
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3. Histone acetylation
Evidence has established that histone acetylation is associated with gene activation. A genome-
wide study demonstrated that all forms of histone acetylation are positively correlated with 
gene expression [10]. Histones contain amino acids with basic side chains that are positively 
charged and attracted to the negatively charged genomic DNA. Ultimately, histone acetylation 
reduces the positive charge on histones and decreases the interaction between nucleosomes 
and DNA. Generally, histone acetylation is greater in the promoters of active genes and influ-
ences both the initiation and elongation of gene transcription. Histone acetylation also stabilizes 
the binding of chromatin remodeling factors at promoter regions and induces nucleosomes 
unfolding as well as reduces nucleosome occupancy. The acetylation state of a chromatin leads 
to the structural modification of the nucleosome. Acetylated (or hyperacetylated) chromatin 
is in a relaxed confirmation and associated with active transcription. In contrast, deacetylated 
(or hypoacetylated) chromatin is condensed and supercoiled, and is associated with transcrip-
tional silencing (and, in the context of cancer, the inhibition of tumor suppressor genes).
Histone acetylation is a rapid and reversible process controlled by histone acetyltransferases 
(HATs) and histone deacetylases (HDAC)s. The HATs transfer acetyl groups from acetyl-
coenzyme A (CoA) to the ε-amino groups of lysine residues in histone tails, which results 
in gene activation. HATs contain a bromodomain that recognizes and binds to acetylated 
histones, categorized into three major families, GNAT (GCN5 and PCAF), MYST (Tip60 and 
MOF), and CBP/p300. The HDACs remove acetyl groups from lysine residues, leading to 
gene silencing. Sequence homology, subcellular location, and the features of the catalytic site 
have been used to classify the 18 members of the human HDAC family into 4 groups: class 
Table 1. Histone modifying enzymes involved in metastasis.
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I (HDACs 1, 2, 3, and 8), class II (HDACs 4, 5, 6, 7, 9, and 10), class III (SIRT1, SIRT2, SIRT3, 
SIRT4, SIRT5, SIRT6, and SIRT7), and class IV (HDAC11) [11]. Class I HDACs have sequence 
homology to class II HDACs and class IV HDACs but not class III HDACs. Class I, II, and IV 
HDACs are zinc-dependent, whereas class III HDACs are nicotinamide adenine dinucleo-
tide (NAD)+-dependent. Genome-wide mapping of the binding of HATs and HDACs to the 
human genome demonstrate that these enzymes regulate the activation and repression of 
transcription, respectively. The dysfunctional balance between acetylation and deacetylation 
is clearly associated with human disease and tumorigenesis.
p300 cooperates in an epigenetic manner with a DOT1L-c-Myc complex to induce EMT 
in breast metastasis [12]. The elevated level of p300-DOT1L-c-Myc is associated with the 
acquisition of CSC-like properties during breast carcinogenesis, which implies that p300 
functions as a potential oncogene to influence the clinical outcome of breast cancer. In 
addition, transforming growth factor-beta (TGF-β) and WNT co-operated to mediate 
EMT. TGF-β induces the translocation of β-catenin to the nucleus where it binds to T- cell 
Factor (TCF); this complex recruits p300/CBP to assemble a transcriptional complex on tar-
get gene promoters that promotes EMT signaling. Intriguingly, over-expression of SNAIL/
SLUG up-regulates TGF-β-receptor 2 (TGFBR2) expression with an increase of H3K9 acety-
lation on TGFBR2 promoter to increase TGF-β signaling [13]. In contrast, however, p300 was 
reportedly recruited by the hepatocyte nuclear factor (HNF) 3 to the E-cadherin promoter, 
increasing expression, and thus reducing the metastatic potential of breast cancer cells [14]. 
Similarly, the p300-CBP-associated factor (PCAF) has functions that can differ among can-
cer types. PCAF is an anti-oncogene and its expression is down-regulated and negatively 
correlated with tumor metastasis in hepatocellular carcinoma (HCC) [15]. This complex 
plays an important role in suppressing EMT and HCC metastasis and by targeting Gli1 
[16]. However, it was also reported that PCAF acetylates the enhancer of zeste homolog 2 
(EZH2) at K348 to augment EZH2 stability, and thus promotes lung cancer cell migration 
and invasion [17]. These reports indicate that the role of PCAF is context-dependent. In 
several breast cancer cell lines, hMOF catalyzes promoter H4K16 acetylation, which is criti-
cal to maintain expression of EMT-related tumor suppressor genes [18]. Consistent with 
this, MOF also acetylates the histone demethylase lysine-specific histone demethylase 1 
(LSD1), to suppress EMT, indicating that MOF is a critical suppressor of EMT and tumor 
progression [19]. Recently, we found that Tip60 appears to be an important regulator of 
TWIST activity by acetylating at H3K73 and H3K76 of the GK-X-GK motif, resulting in an 
interaction between BRD4 and TWIST, hence promoting the aggressiveness of basal-like 
breast cancer (BLBC) [20].
Dysfunctional class I HDAC expression and activity is associated with cancer metastasis. 
HDAC1 regulates invasiveness by increasing matrix metalloproteinase (MMP) expression. 
Furthermore, HIF-2α is a transcriptional regulator of the HDAC1 gene, and hypoxia increase 
HIF-2α and HDAC1 expression [21]. TGF-β-driven E-cadherin silencing and EMT in human 
pancreatic cancer cells also depend on HDAC activity [22]. HDAC1 and HDAC2 form a 
transcriptional repressor complex with SNAIL to downregulate the E-cadherin expression 
of pancreatic cancer cells during metastasis. Intriguingly, SNAIL also recruits the HDAC1/2-
containing SIN3A complex to deacetylate histones on the E-cadherin promoter for gene 
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silencing [23]. In a similar manner, SLUG recruits the HDAC1-containing CtBP complex to 
silence genes by binding to the E-box on the BRCA2 promoter [24]. ZEB1/2 also recruits the 
CtBP/HDAC1 complex to the E-cadherin promoter, while ZEB1 recruits SIRT1, a class III 
HDAC, to silence E-cadherin and promote EMT and metastasis in prostate cancer cells [25, 
26]. Moreover, ZEB1-induced EMT is accomplished by repression of other epithelial genes, 
including EPCAM, ESRP1 and RAB25, and is accomplished by a reduced acetylation of H3K9 
and H3K27 at their promoters. In fact, evidence suggests that H3K27 deacetylation is a key 
epigenetic event in ZEB1-induced transcriptional reprogramming [27]. In addition to the EMT 
transcriptional factors, HDAC1 co-purifies with TCF12 and promotes migration and invasion; 
elevated expression of TCF12 and HDAC1 correlate with a poor prognosis in gallbladder can-
cer. These findings suggest that this HLH transcription factor TCF12 could also target HDACs 
for epithelial gene silencing during EMT [28]. The expression of the HDAC1 and HDAC3 cor-
relates with nuclear receptor (NR) (i.e., ER and PR) status. HDAC assembles a complex with 
ERα that binds to the SLUG promoter to repress expression [29]. Interestingly, HDAC6 and 
SIRT1 counteract the p300-catalyzed acetylation on Cortactin, which enhances its F-actin bind-
ing ability to facilitate EMT and tumor progression [30]. Conversely, HDAC6 and ERα are 
co-localized in the cytoplasm of renal cell carcinoma (RCC) cells and HDAC6 enhances cell 
motility by decreasing acetylated α-tubulin expression [21]. Loss of α-Tubulin acetylation by 
HDAC6 is also associated with TGF-β-induced EMT [31].
Recently, the clinical relevance of HDACs and the therapeutic potential of HDAC inhibitors 
(HDACi) have been reported. HDACi can generally be classified into hydroximates, cyclic 
peptides, aliphatic acids, and benzamides [32], and grouped according to their specificity. 
Thus far three HDACi: vorinostat (SAHA), romidepsin (Istodax) and PTCL (Belinostat or 
Beleodaq) are approved by the FDA for some T-cell lymphomas [33]. However, these mol-
ecules have not produced favorable and expected outcomes in solid tumors. Currently, a 
number of small molecules HDACi were investigated in clinical trials with variety of solid 
neoplasms, including breast cancer, either alone or in combination with hormonal treatments. 
Entinostat (MS-275), a benzamide with high specificity for the class I HDACs, is currently in a 
phase II/III trial for advanced ER+ breast cancer [34, 35]. Vorinostat exerts EMT reversal effects 
by restoring the expression of E-cadherin. An expanded screen on 41 HDACi further iden-
tified 28 HDACi compounds, such as the class I-specific inhibitors Mocetinosat, Entinostat 
and CI994, that restore E-cadherin and ErbB3 expressions in ovarian, pancreatic and bladder 
carcinoma cells [36]. Mocetinostat, but not other HDACi, specifically interferes with ZEB1 
function, restores miR-203 expression, represses stemness properties, and induces sensitiv-
ity against chemotherapy by restoring histone acetylation on the E-cadherin promoter [37]. 
Given that persistent genes activation may require targeting of multiple epigenetic silencing 
machineries, a combination of HDACi with anticancer drugs and/or radiotherapy demon-
strate synergistic or additive effects in clinical trials. For example, HDACi have been utilized 
in combination with 5 Aza-dC as a synergistic strategy [38]. However, recent reports also 
found that HDACi could promote EMT in prostate and nasopharyngeal cancer cells [39, 40], 
indicating the application of HDACi in anti-cancer therapy is cancer-context dependent and 
may limit application.
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4. Histone methylation
Histone methylation occurs at specific lysine or arginine residues on the histone tails. This 
modification is associated with either transcriptional activation or repression. Histone meth-
ylation does not change the electrostatic charge of histones or affect the chromatin structure. 
The functional effects of histone methylation are affected by both the position of the modified 
residues and number of methyl groups. Histone methyltransferases (HMTs) transfer methyl 
groups from S-adenosylmethionine (SAM) to either lysine or arginine residues, whereas his-
tone demethylases (HDMs) remove methyl groups. The HMTs and HDMs specifically cata-
lyze particular lysine or arginine residues.
4.1. Lysine methylation
Methylation of lysine residues on histones was first identified in the 1960s. Histone lysines can 
have four states of methylation at different lysine sites. Histones H2B lysine 5 (H2BK5), H3K4, 
H3K9, H4K20, H3K27, H3K36, and H3K79 are subject to unmethylated, mono-methylation 
(me1), di-methylation (me2), or tri-methylation (me3) on the ε-amino groups of lysine resi-
dues. These lysine methylations change the chromatin structure and regulate gene transcrip-
tion. Histone lysine methylation is a reversible modification and is maintained by the balance 
lysine methyltransferases (KMTs) and lysine demethylases (KDMs). The KMTs recruit SAM 
as a cofactor and catalyze the addition of methyl groups to lysine residues through the SET 
domain. The KMTs are grouped into the SET domain-containing enzyme families (KMT1–3 
and KMT5–7), the KMT4/DOT1 family, and others. The KDMs include the flavin adenine 
dinucleotide- (FAD-) dependent monoamine oxidase family (KDM1/LSD), the Jumonji C 
domain-containing demethylase (JMJD) families (KDM2–6), and others. Methylation of H3K4, 
H3K36, and H3K79 usually correlate with gene activation, whereas methylation of H3K9, 
H3K20, H3K27, and H3K56 are associated with transcriptional silencing.
4.1.1. Transcriptional activation and lysine methylation
H3K4: H3K4 methylation (H3K4me) is present in euchromatic regions and is usually associ-
ated with transcriptional activation. H3K4me3 occurs principally at the 5′ end of actively tran-
scribed genes, near the transcription start site (TSS). H3K4me2 is located throughout genes, 
but frequently found towards the middle of the coding region of transcribed genes, and 
H3K4me1 is more abundant at the 3′ ends [41]. H3K4me2 marks can be present at both active 
and inactive euchromatic genes, whereas H3K4me3 is present exclusively at active genes. 
H3K4me favors transcriptional activation by facilitating H3 acetylation and the recruitment 
of RNA polymerase II, but it also antagonizes gene repression by preventing the binding of 
nucleosome remodeling and deacetylase co-repressor complexes, such as NuRD, and interfer-
ing with substrate recognition by the variegation 3–9 (SUV39H) methyltransferases [42]. The 
balance between KMTs and KDMs is an important dynamics for H3K4me and the regulation 
of gene transcription. More than ten H3K4 KMTs have been identified, including the mixed-
lineage leukemia (MLL)1–4 proteins, along with Set 1a and Set 1b, Ash1L, Set7/9, and also the 
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SET and MYND domain-containing enzymes (SMYD) family members (SMYD1 and SMYD3). 
SMYD are involved in many cellular processes, including tumorigenesis and invasiveness. 
For example, SMYD3 is a novel histone H3K4-specific N-lysine di- and tri-methyltransferase, 
and highly characteristic active transcription. SMYD3 exerts its effects on initiation, invasion 
and metastasis of diverse tumors (e.g., esophageal squamous cell carcinoma (ESCC), gastric 
cancer, HCC, cholangiocarcinoma, breast cancer, prostate cancer, and leukemia). SMYD3 
stimulates EZR and LOXL2 transcription to enhance proliferation, migration and invasion 
by directly binding to sequences of the promoter regions of these target genes [43]. SMYD3 
is also capable of increasing cell migration through MMP-9 expression [44]. The MLL pro-
teins (Trithorax homologs in Drosophila) are important for the regulation of developmental 
genes such as the Hox cluster, and deficiency of MLL1 or MLL2 causes embryonic lethality 
[45]. MLL1 coordinates with HIF1α and regulates hypoxia-induced HOTAIR expression to 
facilitate tumorigenesis [46]. In addition, MLL1 interacts with β-catenin to promote cervical 
carcinoma cell tumorigenesis and metastasis [47]. KMT2B/MLL2 is highly expressed in ESCC 
and promotes tumor progression by inducing EMT [48]. Another member of MLL family, 
MLL3 is reportedly mutated in multiple cancers. MLL3 regulates many migration-related 
genes and downregulation of MLL3 has a profound impact on the progression of ESCC [49]. 
Furthermore, Kim et al. [50] showed that KMT2D/MLL4 expression is associated with poor 
survival in breast cancer and regulates tumor proliferation and invasiveness.
Histone lysine methylation is a reversible process. H3K4 is demethylated by the KDM1 family 
(LSD1 and LSD2), the KDM2 family (FBXL10 and FBXL11), and the KDM5 family (JARID1A, 
JARID1B, JARID1C, and JARID1D) as well as JARID2 and NO66. The LSD subgroup of KDMs 
specifically targets the mono- and dimethylated lysines. This group demethylates substrates 
through a flavin adenine dinucleotide-dependent oxidative reaction, producing lysine and 
formaldehyde. KDM1A/LSD1 was the first H3K4 lysine-specific demethylase to be identi-
fied. We and others demonstrated that SNAIL recruits LSD1 to epithelial gene promoters 
with demethylation of H3K4me2 and subsequent silencing of target genes to enhance tumor 
metastasis [51]. SLUG also interacts with LSD1 to facilitate tumor metastasis [52]. In addi-
tion, both SNAIL and SLUG recruit LSD1 and bind to a series of E-boxes located within the 
BRCA1 promoter to repress BRCA1 expression. LSD1 overexpression promoted metastasis 
whereas knockdown of LSD1 inhibited tumor spread, suggesting that LSD1 is a key regulator 
of ESCC metastasis [53]. LSD1 and LSD2 act differently in the regulation of gene transcrip-
tion and chromatin remodeling. However, both of KDM1A and KDM1B are overexpressed 
in invasive breast carcinoma, and depletion results in high levels of H3K4me1–2. The KDM5/
JARID1 family is frequently found in the promoter region of transcriptionally active genes, 
and results in repressed expression of the target genes. KDM5A is highly expressed in ovar-
ian cancer tissues and facilitates EMT and metastasis [54]. KDM5A promotes an increase in 
TNC expression, which augments breast cancer cell invasion and metastasis [55]. Reports 
indicate that, in gastric cancer cell, KDM5A is induced by TGF-β1 and recruited by p-SMAD3 
to silence the E-cadherin promoter and promote tumor progression [56]. KDM5B plays a role 
in cell differentiation, stem cell self-renewal and other developmental progresses. Recent 
studies showed that KDM5B expression was increased in breast, bladder, lung, prostate and 
many other tumors and promote tumor initiation, invasion and metastasis. Mechanistically, 
KDM5B exerts its function through modulation of H3K4me3 at the PTEN gene promoter [57]. 
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KDM5C/JARID1C is overexpressed in breast cancer, and its expression is significantly asso-
ciated with metastasis. This demethylase modulates the status of H3K4 methylation in the 
breast cancer metastasis suppressor-1 (BRMS1) promoter, and thereby controls the expression 
of BRMS1 to inhibit tumor progression. Accordingly, the expression of KDM5C and BRMS1 
are inversely correlated in human breast cancer [58].
H3K36: Because the level of H3K36me3 is high at the promoter site in active genes, H3K36me3 
is involved in active transcription. In contrast, the H3K36me1 signal has a low association with 
active promoters. H3K36 is methylated by the KMT3 family (SETD2 and NSD1) as well as by 
NSD2, NSD3, SMYD1, SMYD2, SMYD3, SMYD4, and SMYD5. SETD2 plays a tumor suppres-
sor role in tumor metastasis. Interestingly, SETD2 is frequently either deleted or mutated [59]. 
In contrast, H3K36 is demethylated by the KDM2 family (FBXL10 and FBXL11), the KDM4/
JMJD family (JMJD2A, JMJD2B, and JMJD2C), and NO66. KDM2A expression is increased in 
breast cancer and associated with poor clinical outcomes [60]. KDM2A promotes lung tumori-
genesis by epigenetically enhancing ERK1/2 signaling through demethylation of H3K36 [61]. 
In addition, KDM8/JMJD5 also demethylates H3K36me2, and overexpression of JMJD5 pro-
motes cell invasion and is significantly correlated with clinical stage, histological grade and 
lymph node metastasis [62].
H3K79: H3K79me3 is associated with active transcription in yeast, whereas it is localized 
at both active and silent promoters in humans. H3K79me1 and H3K79me2 do not have any 
association with either active or silent promoters. H3K79 is methylated by the KMT4 family 
(DOT1L) and demethylated by PHF8 [63]. Methylation of H3K79 has been implicated in cell 
cycle regulation and the DNA damage response [63]. Disruption of this methylation can lead 
to cancers, making DOT1L a potential therapeutic target for cancers such as leukemia [64]. 
More recently, DOT1L has been implicated in the stimulation of proliferation, self-renewal, 
and metastatic potential of breast cancer cells [65]. DOTL1 cooperates with c-Myc-p300 com-
plex to epigenetically activate EMT regulators in breast cancer progression. Clinically, DOTL1 
expression is associated with poorer survival and aggressiveness of breast cancer [12]. PHF8 
is highly expressed in metastatic prostate tissues and plays an important role in controlling 
invasion and metastasis [66]. PHF8 also interacts with β-catenin, and binds to the promoter 
region of vimentin, leading to the promotion of gastric cancer progression and metastasis [67].
4.1.2. Transcriptional repression and lysine methylation
H3K9: The methylation of H3K9 (H3K9me) was the first mechanism of gene repression 
to be linked to KMT. Studies in Drosophila showed that the gene Su(var)39, later shown to 
encode a H3K9 HMT, had an important role in the regulation of position-effect variegation 
[68] and similar enzymes were subsequently discovered in humans (SUV39H1/H2, G9a and 
Riz1 among others) [69]. H3K9 methylation is important for chromatin condensation and 
heterochromatin formation. H3K9me is recognized and bound by heterochromatin pro-
tein 1 (HP1), which recruits SUV39H, to reinforce the silencing process. H3K9 methylation 
plays a critical role in the formation of transcriptionally silent heterochromatin and the 
stable inheritance of the heterochromatin state. H3K9me1 and H3K9me2 are associated 
with euchromatic gene repression, whereas H3K9me3 is associated with stably silenced 
heterochromatin. H3K9me2 marks contribute to the maintenance of gene repression 
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in differentiated tissues in large genomic regions known as ‘large organized chromatin 
K9–modifications (LOCKs)’, and require the activity of the methyltransferase G9a [70]. 
H3K9me is methylated by the KMT1 family (SUV39H1, SUV39H2, G9a, GLP, SETDB1, and 
SETDB2). H3K9 is demethylated by the KDM1 family (LSD1), the KDM3 family (JMJD1A, 
JMJD1B and JMJD1C), and the KDM4 family (JMJD2A, JMJD2B, JMJD2C, and JMJD2D) 
as well as PHF8 and KDM7A/JHDM1D. SUV39H1 generates H3K9me3, and is involved 
in breast carcinogenesis. In addition, we found that SUV39H1 cooperates with SNAIL to 
repress the expression of E-cadherin. Knockdown of SUV39H1 blocked the formation of 
H3K9me3 and DNA methylation and inhibited cell migration, invasion and metastasis of 
BLBC [71]. Furthermore, we demonstrated that knocking down G9a resulted in suppression 
of H3K9 methylation and inhibition of tumor cell migration or invasion [72]. Mechanically, 
we found that G9a interacted with SNAIL and is critical for SNAIL-mediated E-cadherin 
repression in human breast cancer. Consistent with our research, Huang et al. [73] demon-
strated that knocking down G9a or pharmacological inhibition of its activity suppressed 
tumor cell growth, colony formation, invasion and migration in non-small-cell lung cancer 
cells (NSCLC). G9a is also associated with an increased expression in lung cancer [74]. 
SETDB1 is the most significantly up-regulated epigenetic regulator in human HCCs and 
prostate cancer [75, 76]. Knockdown of SETDB1 decreases cell migration and invasion 
and reduces EMT and CSC properties [77]. SETDB1 indirectly up-regulates STAT3 expres-
sion and induces TWIST. KDM3A catalyzes the demethylation of H3K9 associated with 
transcriptional repression, resulting in the derepression and activation of genes involved 
with invasion and metastasis [78]. Global gene expression profiling demonstrated KDM3A 
regulates genes and pathways that augment cell migration and metastasis. KDM3A pro-
motes both migration in vitro and metastasis in vivo by targeting melanoma cell adhesion 
molecule (MCAM) [79]. Surprisingly, increased expression of KDM3B correlates with 
improved clinical outcomes [80]. Accordingly, JMJD1B and JMJD2B are associated with 
PRL-3, a gene crucial to metastasis in colorectal cancer (CRC). However, JMJD1B seems 
to be a candidate tumor suppressor while JMJD2B seems to be a potential oncoprotein 
for CRC metastasis and progression [81]. With respect to the breast cancer, KDM4A is a 
regulator of cancer cell growth and metastasis, which correlates with breast cancer progres-
sion, and is associated with the attenuation of the tumor suppressor ARHI [82]. KDM4B is 
physically associated with β-catenin and binds to the promoter of the β-catenin target gene 
vimentin to increase its transcription by inducing H3K9 demethylation [83]. Inhibition of 
JMJD2B attenuates migration and invasion of gastric cancer cells in vitro and metastasis in 
vivo. KDM4C expression correlates significantly with genes driving metabolic alterations in 
breast cancer; the mechanism involves an interaction between KDM4C and HIF1α, which is 
recruited to a subset of genes involved in metabolic remodeling and metastasis [84].
H4K20: H4K20 methylation is also associated with repressed chromatin. A recent genome-
wide analysis demonstrated that H4K20me3 was associated with heterochromatin and 
played a pivotal role in chromatin integrity. In addition, loss of histone H4K20me3 predicts 
poor prognosis in breast cancer and is associated with invasive activity. On the other hand, 
H4K20me1 is located in the promoters or coding regions of active genes and co-localizes with 
H3K9me1, which suggest that H4K20me1 is associated with transcriptional activity. H4K20 is 
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methylated by the KMT5 family (PR-Set7, SUV4-20H1, and SUV4-20H2) and the KMT7 family 
(SET7/9). KDMs that catalyze H4K20 demethylation have not been reported. Moreover, ectopic 
expression of SUV420H1 and SUV420H2 in breast cancer cells suppressed cell invasiveness, 
whereas knockdown of SUV420H2 activated invasion by normal mammary epithelial-cell in 
vitro [85]. Through its repressive H4K20me3 mark, SUV420H2 silences several key drivers of 
the epithelial state. Knockdown of SUV420H2 elicited MET on a molecular and functional 
level. An analysis of human pancreatic cancer biopsies suggests that high levels of SUV420H2 
correlate with a loss of epithelial characteristics and progressively invasive cancer [86]. SET8 
(also known as PR-Set7/9, SETD8, KMT5A), a member of the SET domain-containing meth-
yltransferase family that specifically target H4K20 for monomethylation, physically interacts 
with TWIST to promote EMT and invasion by breast cancer cells [87]. Interestingly, SET8 acts 
as a dual epigenetic modifier on the promoters of E-cadherin and N-cadherin through its 
H4K20 monomethylation activity [88]. These bipolar roles of SET8 in EMT were also found in 
prostate cancer, which were mediated by ZEB1 [89]. A recent report indicates that the activa-
tion of the Shh pathway is required for EMT in NSCLCs [90]. SET7-mediated Gli3 methyl-
ations contribute to the tumor growth and metastasis in NSCLCs in vitro and in vivo [91].
H3K27: Another important repressive mark is H3K27 methylation which plays an essential 
role in embryogenesis, cell differentiation and organogenesis. H3K27me3 is associated with 
constitutive heterochromatin and maintenance of gene repression during early development. 
According to a genome-wide analysis, the levels of H3K27me2 and H3K27me3 are elevated in 
silent promoters and reduced in both active promoters and genic regions, whereas the level of 
H3K27me1 is high in promoters engaged in active transcription, especially downstream of the 
TSS [92, 93]. In embryonic stem cells (ESCs), H3K27 methylation usually overrides the effect 
of H3K4me3 in bivalent regions, maintaining them in a repressed state. Upon differentiation, 
these regions become exclusively marked by either of these modifications, leading to gene acti-
vation or repression [92]. H3K27 methylation is catalyzed by the polycomb repressive complex 
2 (PRC2), which is composed mainly of suppressor of zeste 12 (SUZ12), embryonic ectoderm 
development (EED) and EZH2. H3K27 is demethylated by the KDM6 family (KDM6A/UTX 
and KDM6B/JMJD3), as well as UTY and JHDM1D [94, 95]. EZH2 is overexpressed in prostate 
and breast cancers and correlates with poor prognosis. Interestingly, EZH2 is essential for 
CSC self-renewal, and these CSCs provide the seeds for metastatic dispersal and differentiate 
into tumor-associated endothelial cells. Pre-clinical studies showed that EZH2 can silence 
several anti-metastatic genes (e.g., E-cadherin and tissue inhibitors of metalloproteinases), 
thereby favoring cell invasion and anchorage-independent growth. Accordingly, Tiwari and 
colleagues delineated an elegant pathway wherein TGF-β induces EZH2 expression to elicit 
EMT programs and metastasis of breast cancers by reprogramming the epigenome [96]. EZH2 
represses TIMP2 transcription, which leads to increased activity of MMP-2 and MMP-9 and 
the invasive capacity of BLBC cells [97]. In pancreatic cancer cells, SNAIL recruits PRC to the 
E-cadherin promoter by binding to SUZ12 [98]. Increased KDM6A expression is associated 
with poor prognosis, along with derepression/activation of genetic programs that induce cell 
proliferation, luminal to basal-like transition, and metastasis. Furthermore, the function of 
KDM6A correlates with the activity of the MLL4, and increased expression of these epigenetic 
enzymes correlates with poor survival outcomes in breast cancer [50]. UTX interacts with the 
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MLL4 complex to activate several pro-metastatic genes including MMP9 and SIX1, leading 
to increased EMT and metastasis of breast cancer [50]. In colon cancer, KDM6A not only 
demethylates H3K27me3 at the E-cadherin promoter but also recruits CBP to the E-cadherin 
promoter, resulting in increased H3K27ac [99]. However, it was also reported that KDM6A 
inhibited EMT by epigenetic repression of EMT genes in cooperation with LSD1 and HDAC1 
[100]. Therefore, the role of KDM6A an EMT suppressor or enhancer requires further inves-
tigation. KDM6B expression is also increased in invasive breast carcinomas and enforcing 
KDM6B overexpression induces EMT, invasive migration, stem cell-like traits, and metastatic 
properties. The mechanism involves demethylation associated with increased SNAIL or 
SLUG expression mediating the EMT [101]. Interestingly, KDM6B also modulates the tumor 
microenvironment and promotes melanoma progression and metastasis through upregula-
tion several targets of NF-κB and BMP signaling, including stanniocalcin 1 (STC1) and che-
mokine (C-C motif) ligand 2 (CCL2) [102].
In summary, histone lysine methylation modulates chromatin accessibility, transcriptional 
status, and control of tumor suppressor and oncogene expression in aberrant cell metastasis. 
Dynamic regulation of the either permissive or repressive histone methylation at different 
genomic loci and through different molecular mechanisms facilitates the dynamic EMT process.
4.2. Arginine methylation
Histone arginine methylation also occurs in many arginine sites, histone H3 arginine 2 (H3R2), 
H3R8, H3R17, H3R26, and H4R3 undergo monomethylation (me1), symmetrical dimethylation 
(me2s), or asymmetrical dimethylation (me2a) on the guanidinyl groups of arginine residues. 
The N-arginine methyltransferases (PRMTs) are a class of enzymes that transfer a methyl group 
from SAM to the guanidino nitrogen of arginine. PRMTs generate three arginine methylation 
forms: monomethylarginine (MMA), asymmetric dimethylarginine (aDMA), and symmetric 
dimethylarginine (sDMA). Human PRMTs are composed of nine members that are categorized 
into three groups based on the type of arginine methylation reaction each member catalyzes. 
Type I is comprised of PRMT1, PRMT2, PRMT3, CARM1/PRMT4, PRMT6, and PRMT8; these 
catalyze both mono-methyl and asymmetric dimethyl arginine reactions. The type II group is 
made up of two members, PRMT5 and PRMT9, which catalyze both mono-methyl arginine 
and symmetric dimethyl arginine. Finally, PRMT7 is, at this point, considered the only bona 
fide type III methyltransferase and can generate only mono-methyl arginines. Many studies 
demonstrated that PRMTs regulate a wide range of genetic programs and cellular processes 
including cell cycle, RNA splicing and differentiation. Although the consequence of lysine 
methylation is relatively well studied, the role of PRMT action in tumorgenesis is poorly 
understood. Here, we provide a description of these PRMTs regarding tumor metastasis.
PRMT1: PRMT1 has been extensively studied in many fields. Its activity is responsible for a 
substantial percentage of methylated arginine residues and modulates a wide range of cell 
types. Specifically, asymmetric dimethylation on H4R3 by PRMT1 is involved in transcrip-
tional activation, thereby driving oncogenic pathways. PRMT1 is an important regulator of 
EMT, cancer cell migration, and invasion. PRMT1 can generate H4R3me2a on the promoter 
region of ZEB1 and TWIST, which play a critical role in EMT [103, 104]. Furthermore, PRMT1 
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is overexpressed in melanoma; silencing PRMT1 significantly suppresses tumor growth and 
metastatic ability by targeting activated leukocyte cell adhesion molecule (ALCAM) [105]. 
Similarly, downregulation of PRMT1 inhibits cell migration and invasion in HCC and oral 
squamous cell carcinoma (OSCC) [106, 107]. Because of complex alternative splicing in the 
5′ region of its pre-mRNA, there are seven distinct PRMT1 isoforms [108]. Each of these iso-
forms, named PRMT1v1-v7, has distinct characteristics in terms of expression. PRMT1v1 is 
the most abundantly expressed isoform and likely represents the isoform that is described as 
PRMT1 in most reports. The expression of alternatively spliced PRMT1 (PRMT1v2) isoform, 
which is generated through inclusion of alternative exon 2, is significantly altered in breast 
cancer and promotes invasiveness. The RNA binding protein RALY regulates the PRMT1v2 
isoform and promotes metastatic potential [109].
PRMT2: PRMT2 is also reported to be overexpressed in breast cancer [110]. PRMT2 inter-
acts with many NRs, including ERα and ERβ in vitro [111]. Interestingly, the activation of 
these receptors within cells has both distinct and in some cases opposing effects, which sug-
gests that the functional role(s) PRMT2 are quite diverse. Recently, four alternatively spliced 
PRMT2 isoforms (PRMT2L2, PRMT2α, β, and γ) in addition to the original PRMT2 isoform 
were identified [112]. Several splice variants (i.e., PRMT2-α, −β, −γ) were identified as induced 
in breast cancer, particularly in ER, PR-positive breast cancer [110]. PRMT2 directly binds and 
enhances estrogen-mediated transactivation of ERα, and enhances the promoter activity of 
the downstream target gene SNAIL. These findings suggest that the increased PRMT2 expres-
sion is associated with breast aggressiveness and metastasis [110].
PRMT4: PRMT4, more commonly known as coactivator-associated arginine methyltransfer-
ase 1 (CARM1), is involved in the regulation of a number of cellular processes including 
transcription, pre-mRNA splicing and cell cycle progression. The expression of CARM1 is 
dysregulated in colorectal, prostate and breast cancer. CARM1 methylates the chromatin-
remodeling SWI/SNF core subunit, BAF155 in breast cancer [113]. The methylation of arginine 
1064 residue of BAF155 is associated with breast cancer recurrence and metastasis, indicating 
that CARM1 plays an important role in tumorigenic activity through BAF155. Accordingly, 
CARM1-induced tumorigenic effects and its expression is increased in invasive breast cancer, 
and correlates with a high tumor grade [114]. Interestingly, the CARM1 gene also transcribes 
four isoforms: the primary isoform CARM1 (CARM1v1) and three alternative isoforms, v2, v3 
and v4 [115]. Whether these isoform are responsible for the methylation of distinct substrates 
and their individual functions requires further study.
PRMT5: PRMT5 is a type II enzyme that generates symmetric dimethylarginine (sDMA). 
The PRMT5 symmetrically methylates H3R8 site and functions in gene silencing. H3R8me2s 
strongly associates with H4R3me2s, because both modifications are catalyzed by PRMT5. 
However, acetylation of H3K9 and H3K14 prevents H3R8 methylation. PRMT5 also acts 
as a novel cofactor of SHARPIN (Shank-associated RH domain interacting protein), which 
plays a central role in controlling lung cancer cell metastasis. SHARPIN-PRMT5 is essen-
tial for the monomethylation of histones at key metastasis-related genes [116]. PRMT5 has 
another distinct function; PRMT5 coordinates with multiple Mediator complex subunits to 
dimethylate H4R3 at the promoter regions of immune response genes and C/EBPβ target 
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genes [117]. Conversely, PRMT5 methylation of histone H3R2 recruits WDR5 and the MLL 
complex, stimulating H3K4 methylation and euchromatin maintenance [118]. In the context 
of cancer metastasis, PRMT5 is involved in TGF-β-WDR77 signaling, which induces cancer 
cell invasion [119]; this report indicates PRMT5 interacts with the WDR77 complex to catalyze 
arginine methylation. With respect to the acquisition of EMT via TGF-β signaling, epigenetic 
PRMT5-WDR77 activity is necessary for tumor invasion and metastasis. Furthermore, PRMT5 
appears to be recruited by AJUBA to SNAIL and functions as a co-repressor. PRMT5, AJUBA 
and SNAIL form ternary complex to repress E-cadherin, concomitant with increase arginine 
methylation at the locus [120]. PRMT5 also modulates metastasis by methylating KLF4. 
Methylation blocks ubiquitylation of KLF4 by the von Hippel–Lindau tumor suppressor, and 
as a result, arginine methylation of KLF4 via PRMT5 increases the level of KLF4 protein and 
increases the probability of breast carcinogenesis [121].
PRMT6: PRMT6 primarily catalyzes asymmetric dimethylation of H3R2. H3R2me2a coun-
ter-correlates with the methylation of H3K4, which suggests that H3R2me2a is a repressive 
marker. However, PRMT6 also methylates H3K4 since both H3R2me2a and H3K4me3 mark-
ers are likely to coexist. Furthermore, genome-wide analyses indicate that both H3R2me1 and 
H3R2me2a are associated with active genes [93]. Thus, the data on the H3R2me2a marker are 
contradictory, and further studies are required to resolve this issue. There is also emerging 
evidence of an oncogenic role of PRMT6 in cancer. Overexpression of PRMT6 is associated 
with several cancer types, including breast, cervix, prostate, and lung cancers, indicating that 
PRMT6 might play an important role for the onset, incidence, and metastasis of cancer [122]. 
Furthermore, Dowhan et al. [123] demonstrated a PRMT6-dependent signature that influ-
ences long-term survival in patients with breast cancer.
PRMT7: The oncogenic role of PRMT7 has been emerging over the past few years. There are 
two isoforms, PRMT7α and β, which are active and have slightly different methylation profiles 
and locations. PRMT7α localizes to the cytoplasm and nucleus, whereas PRMT7β is exclusively 
cytoplasmic. R531 of PRMT7 is self-methylated and loss of PRMT7 automethylation leads to 
a reduced recruitment to the E-cadherin promoter by YY1, which consequently derepresses 
E-cadherin expression by decreasing the H4R3me2’s level [124]. In terms of the functional role 
of PRMT7, this methytransferase is highly expressed in breast cancer and induces EMT by 
inhibiting E-cadherin. Baldwin et al. [125] also showed that PRMT7 promotes a well-known 
metastasis mediator, MMP9 and induces breast cancer cell invasion. Importantly, a gene 
expression analysis of independent data sets of more than 1200 breast tumors identified PRMT7 
expression as significantly increased. In addition, this gene is located 16q22, where the chro-
mosomal region was correlated with an increased metastatic potential of breast cancer [126].
PRMT9: PRMT9 and PRMT5 are the only known mammalian enzymes capable of forming 
sDMA residues as type II PRMTs. However, the specificity of these enzymes for their sub-
strates is distinct and not redundant. Interestingly Yang et al. [127] showed that PRMT9 is 
also nonhistone methyltransferase. For example, it methylates the arginine 508 site of the 
alternative splicing factor SAP145. Given that alternative splicing is of paramount importance 
in RNA processing, PRMT9 might play a key role in many cellular programs including cancer 
biology. Recent reports demonstrate that overexpression of PRMT9 strongly promotes HCC 
invasion and metastasis through EMT by regulating SNAIL expression via activation of the 
PI3K/Akt/GSK-3β/SNAIL signaling pathway [128].
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Many HMTs and HDMs inhibitors have been developed and evaluated in clinical trials, 
such as chaetocin, BIX-01294, BIX-01338, UNC0638 and DZNep. Chaetocin, a natural fun-
gal substance, is the first inhibitor of an HMT, which targets SUV39H1 without high selec-
tively [129]. Treatment with Chaetocin induces expression of E-cadherin while reducing 
H3K9me3 but does not produce a global H3K9 methylation on its promoter in multiple 
tumor cells [130]. By the contrast, BIX-01294 specifically reduces the dimethylation of 
H3K9me2 through an inhibition of the enzymatic activities of G9a and GLP [131]. Treatment 
of BIX-01294 activates E-cadherin expression and reverse EMT phenotypes in a variety of 
cancer cells, and is accompanied by reduced H3K9me2 and increased H3K9 acetylation on 
the E-cadherin promoter [132]. Another G9a/GLP inhibitor, UNC0638, was developed with 
higher potency and selectively [133]. UNC0638 treatment not only resulted in lower global 
H3K9me2 levels but also markedly reduced the abundance of H3K9me2 marks at promot-
ers of known G9a-regulated endogenous genes. UNC0638 treatment activates E-cadherin 
expression and reverses EMT in PANC-1 pancreatic cancer cells and triple negative breast 
cancer (TNBC) and suppresses migration and invasion [134]. Because of the importance 
of H3K27 methylation in cancer, several highly specific EZH2 inhibitors have been devel-
oped, such as GSK2816126 and EPZ-6438, which are currently being evaluated in clinical 
trials for lymphoma and solid tumor/lymphoma respectively [135]. Another EZH2 inhibi-
tor, 3-deazaneplanocin A (DZNep), selectively inhibits H3K27me3 and H4K20me3 [136]. 
DZNep dampens TGF-β-induced EMT signals and reduces tumor metastasis in pancreatic 
cancer and colon cancer [136, 137]. We found that Parnate, an LSD1 inhibitor, activates 
E-cadherin expression and suppresses motility and invasiveness in breast cancer cells 
[51]. Two highly specific LSD1 inhibitors, GSK2879552 and ORY-1001 are employed to 
clinical trials for the treatment of small cell lung cancer and acute leukemia [135]. Several 
inhibitors targeting HDMs also have been developed as well. For example, JIB-04, a spe-
cific inhibitor targeting the JMJC-domain, inhibits the activity of H3K4 and H4K9 and 
attenuates lung cancer cell proliferation [138]. The first reported small molecule PRMT 
inhibitors, including AMI-1 and AMI-5 were identified through virtual screening and high 
throughput screening [139]. AMI-1 was reported as type I PRMT and PRMT5 inhibitor 
[140]. AMI-1 inhibits proliferation and decreases cell migratory activity of CRC cells in 
vitro and in xenograft mouse models [141].
5. Histone modification readers
Sometimes, histone modifications can directly regulate the chromatin dynamic. However, 
in most cases, the modifications are recognized by proteins containing distinct recognition 
domains, which act as “readers” and bind to different histone modifications. For example, 
bromodomain acts as lysine acetylation “readers” of modified histones that mediate sig-
naling transduction changes in gene regulatory networks. In the human genome, there 
are 61 bromodomains found within 46 proteins that can be divided into eight families 
based on structure/sequence similarity. Among them, bromodomain and the extra-ter-
minal domain (BET) family recognize acetylated lysine residues in histones H3 and H4. 
BRD4 is a member of the BET family that carries two bromodomains. Recently, our stud-
ies revealed that the di-acetylated TWIST, mediated by Tip60, recruits BRD4 and related 
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transcriptional components to the super-enhancer of its targeted genes during tumor 
progression in BLBC [20]. In addition, pharmacologic inhibition of BRD4 with the BET-
specific bromodomain inhibitors, JQ1 and MS417, effectively reduces WNT5A expression 
and suppresses invasion, CSC-like properties and tumorigenicity of breast cancer cells 
in vitro and in vivo [20]. Given the extensive cancer-related functions of BRD4 and the 
proof-of-concept demonstrated by disruption of the BRD4–acetyl-lysine interactions as a 
therapeutic target, significant efforts have thus been made to develop BRD4 inhibitors 
from both pharmaceutical and academic settings. BRD4 inhibitors have several chemical 
classifications including azepines, 3,5-dimethylisoxazoles, pyridones, triazolopyrazines, 
tetrahydroquinolines (THQs), 4-acyl pyrroles and 2-thiazolidinones [142]. BET inhibitor 
treatment results in AMIGO2 silencing and changes in PTK7 proteolytic processing, and 
thus inhibit melanoma metastasis [143].
Histone methylation provides docking sites and is recognized by specific reader proteins 
that contain a methyllysine binding protein, which has emerged as a focus of epigenetic 
research due to its critical role in gene regulation and oncogenesis. This reader harbors 
specific motifs, including Chromodomain (CD), MBT, WD40 repeat, PHD finger, PWWP, 
Tudor and Ankyrin repeat. Methyllysine binding proteins distinguish methylation marks 
on different residues as well as different methylation states on the same residue and in 
turn mediate distinct downstream functions [144]. CD-containing HP1 proteins were the 
first identified methyl-lysine binding proteins and recognize methylated-H3K9 (methyl-
H3K9) [145]. HP1α was down-regulated in metastatic cells of colon cancer and thyroid 
carcinomas relative to non-metastatic cells, indicating HP1α may be directly involved 
in the silencing of genes that potentiate cancer cell invasive potential and metastasis. 
Recent evidence implicate HP1α in EMT. The association of HP1α to major satellite repeat 
sequences located in pericentric heterochromatin decreased during the initial steps of 
TGF-β-induced EMT in a SNAIL/LOXL2-dependent manner [146]. In addition, HP1α post-
translational modifications could participate in the heterochromatin dynamics associated 
with EMT. In a different set of modifications, four MBT-repeats domain of SFMBT1 recog-
nize H3K4me2/3 and form a stable complex with LSD1. SFMBT1 is essential for SNAIL-
dependent recruitment of LSD1 to chromatin, demethylation of H3K4me2, transcriptional 
repression of epithelial markers, and induction of EMT by TGF-β [147]. H3K4me2/3 is also 
recognized by the WD40 repeat domain of WDR5, which is also important for the assem-
bly and activity of the SET1 protein complex catalyzing H3K4me3 [148]. Under hypoxic 
conditions, WDR5 is induced, interacts with HDAC3 and further recruits SET1 complex to 
activate mesenchymal gene expression to promote EMT [149]. Furthermore, the PRC2 com-
ponent, EED, also contains a WD40 repeat that recognizes H3K27me3. EED recruits PRC2 
to chromatin with pre-existing H3K27me3 to spread the same methylation into adjacent 
regions [150]. Intriguingly, G9a and GLP itself contain a methyl-lysine binding module 
(the ankyrin repeat domains), which generates and reads the same epigenetic mark [151]. 
Several small molecule compounds targeting the lysine methylation reader domain have 
been developed, including UNC1215 and UNC3866 that block the methyl-lysine binding 
mediated by the MBT domain-containing protein L3MBTL3, and the CD-containing pro-
tein CBX4/7 respectively [152, 153]. However, whether these inhibitors reverse EMT and 
tumor progression remains unknown.
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6. Coordinated histone modification regulation
Because different chromatin modifying enzymes coexist in the same protein complex, and 
because diverse catalyzed modifications have been implicated in regulating the same set of genes, it 
is likely that these processes act in concert to orchestrate transcriptional regulation during 
EMT. For example, HDAC1/2, G9a/GLP, LSD1, HP1 and ZEB1/2 were co-purified in the CtBP1 
co-repressor complex [154, 155]. ZEB1/2 could first target the complex to E-cadherin promoter 
to initiate repression. Next, HADC1/2 would deacetylate histones while the primed H3K9 was 
methylated by G9a/GLP. Meanwhile, LSD1, which removes H3K4me1/2, whereby the un-meth-
ylated H3K4 could also prevent H3K9 from re-acetylation [156, 157]. An affinity purification of 
Flag-TWIST identified several components of the NuRD chromatin remodeling complex. Among 
them, TWIST directly interacts with Mi2β, MTA2 and RbAp46 and likely targets the NuRD 
complex for histone deacetylation and chromatin remodeling on E-cadherin promoter. Together, 
these epigenetic events lead to gene silencing and promote EMT and breast cancer metastasis 
[158]. In addition, TWIST was also co-purified with SET8, BRCA1-associated protein (BRAP), 
NF-kB subunit RelA, PPP2CA and HES6 in MCF7 breast cancer cells [88]. SET8 interacts with 
TWIST. However, SET8 and TWIST are functionally interdependent in promoting EMT. SET8 
mediates E-cadherin repression and N-cadherin activation simultaneously via its H4K20 
monomethylation to promote cell invasion and EMT. However, the molecular mechanism that 
underlies the same repressive protein complex that contributes to opposite functions on different 
genomic loci remains an open question. Our recent study found that TWIST is diacetylated by 
Tip60, which was further recognized by BRD4, thereby constructing an activated TWIST/BRD4/P-
TEFβ/RNA-Pol II complex at the WNT5A promoter and enhancer to promote EMT and breast 
cancer cell metastasis [20]. In breast cancer cells, the UTX-MLL4 forms a complex with LSD1/
HDAC1/DNMT1 on the promoter of several EMT-TFs and decreases H3K4mes and H3 acetyla-
tion. UTX facilitates epigenetic silencing of EMT-TFs by inducing competition between MLL4 and 
the H3K4 demethylase LSD1, which results in inhibition of EMT and CSC-like properties [100].
MPP8, another methy-H3K9 binding protein, bridges DNMT3A and G9a/GLP to assemble 
a repressive trimeric protein complex on chromatin by binding to different methyl-lysines. 
MPP8 also couples H3K9 methylation and DNA methylation to silence epithelial genes and 
EMT [159, 160]. Interestingly, MPP8 also cooperates with the SIRT1 in this process through 
a physical interaction [161]. SIRT1 and MPP8 reciprocally promote each other’s function and 
coordinate epithelial gene silencing and EMT. SIRT1 antagonizes PCAF-catalyzed MPP8-K439 
acetylation to protect MPP8 from ubiquitin-proteasome-mediated proteolysis. Conversely, 
MPP8 recruits SIRT1 for H4K16 deacetylation after binding to methyl-H3K9 on target pro-
moters. Therefore, MPP8 not only promote DNA-methylation but also H4K16 deacetylation 
to fine-tune the transcriptional regulation of EMT.
7. Conclusions and perspectives
Increasing evidences show that aberrant profiles of histone modifications contribute to a 
dysregulation those results in the metastatic cascade. The biochemically reversible nature 
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of histone modifications provides a platform for rapid changes in a variety of epithelia and 
mesenchymal genes during EMT and MET. In concert with different ETM-TFs and oncogenic 
signaling, pleiotropic histone modifications form a sophisticated and regulated network to 
coordinate the plasticity and dynamic change required for EMT.
Recent research identifies the critical role of histone modifications in metastasis, but leaves 
many important, open questions. First, do tumor microenvironmental signals trigger 
the formation of histone modification enzyme complexes present on different EMT-TFs? 
Whether these extrinsic signals affect enzyme activity indirectly through intracellular sig-
naling pathways or directly through the EMT-TFs remains to be determined. Second, how 
do these EMT-TFs form distinct complexes that coordinate the epigenetic regulation of gene 
expression programs during EMT? Third, EMT is usually activated only transiently and par-
tially. Therefore, which and how do different histone modifying enzymes and the catalyzed 
modifications contribute to these dynamic changes? Finally, what consequences do epigenetic 
instabilities have on cancer cell fitness? Do these activities increase plasticity and/or lead to 
vulnerabilities that it could influence the metastasis?
We know that histone modification enzymes are highly correlated with tumor progression 
and a poor clinical outcome. Therefore, these enzymes can serve not only as effective bio-
markers for earlier diagnosis, but also present multiple therapeutic opportunities. Over the 
last decade, considerable progress has been made in the discovery and development of potent 
and selective small molecule inhibitors targeting specific histone modifiers. Many of these 
molecules are currently under extensive preclinical testing or being evaluated in clinical tri-
als. These inhibitors show great potential as clinically useful drugs. Additionally, inhibitors 
to specific histone modifying enzymes could serve as useful chemical probes to characterize 
the function of different epigenetic pathways in EMT in vivo as well as many other important 
pathological diseases.
In all, advances in our understanding of the landscape of histone modifications in metas-
tasis will provide a better sense of the molecular mechanisms associated with metastasis 
and thus help speed the development of new therapeutic strategies and biomarkers for 
metastasis.
Acknowledgements
We thank Dr. Cathy Anthony for the critical editing of this manuscript. Our research was 
supported by the Shared Resources of the University of Kentucky Markey Cancer Center 
(P30CA177558). Our research was also supported by grants from American Cancer Society 
Research Scholar Award (RSG13187) and NIH (P20GM121327 and CA230758) (to Y Wu).
Conflict of interest
The authors have declared that no conflict of interests exists.
Cancer Metastasis56
Author details
Zhaoping Qiu1,2, Jianlin Wang1,2 and Yadi Wu1,2*
*Address all correspondence to: yadi.wu@uky.edu
1 Department of Pharmacology and Nutritional Sciences, University of Kentucky School of 
Medicine, Lexington, KY, USA
2 Department of Markey Cancer Center, University of Kentucky School of Medicine, 
Lexington, KY, USA
References
[1] Van’t Veer LJ, Weigelt B. Road map to metastasis. Nature Medicine. 2003;9:999-1000
[2] Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in 
metastatic sites. Nature Reviews. Cancer. 2002;2:563-572. DOI: 10.1038/nrc865
[3] Pantel K, Brakenhoff RH. Dissecting the metastatic cascade. Nature Reviews. Cancer. 
2004;4:448-456. DOI: 10.1038/nrc1370
[4] Thiery JP. Epithelial-mesenchymal transitions in tumor progression. Nature Reviews. 
Cancer. 2002;2:442-454
[5] Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in devel-
opment and disease. Cell. 2009;139:871-890. DOI: S0092-8674(09)01419-6 [pii] 10.1016/ 
j.cell.2009.11.007
[6] Brabletz T, Kalluri R, Nieto MA, Weinberg RA. EMT in cancer. Nature Reviews. Cancer. 
2018;18:128-134. DOI: 10.1038/nrc.2017.118
[7] Strahl BD, Allis CD. The language of covalent histone modifications. Nature. 2000;403: 
41-45. DOI: 10.1038/47412
[8] Tessarz P, Kouzarides T. Histone core modifications regulating nucleosome structure 
and dynamics. Nature Reviews. Molecular Cell Biology. 2014;15:703-708. DOI: 10.1038/
nrm3890
[9] Jenuwein T, Allis CD. Translating the histone code. Science. 2001;293:1074-1080. DOI: 
10.1126/science.1063127
[10] Wang Z, Zang C, Rosenfeld JA, Schones DE, Barski A, Cuddapah S, et al. Combinatorial 
patterns of histone acetylations and methylations in the human genome. Nature Genetics. 
2008;40:897-903. DOI: 10.1038/ng.154
[11] de Ruijter AJ, van Gennip AH, Caron HN, Kemp S, van Kuilenburg AB. Histone deacety-
lases (HDACs): Characterization of the classical HDAC family. The Biochemical Journal. 
2003;370:737-749. DOI: 10.1042/BJ20021321
The Landscape of Histone Modification in Cancer Metastasis
http://dx.doi.org/10.5772/intechopen.78383
57
[12] Cho MH, Park JH, Choi HJ, Park MK, Won HY, Park YJ, et al. DOT1L cooperates with the 
c-Myc-p300 complex to epigenetically derepress CDH1 transcription factors in breast 
cancer progression. Nature Communications. 2015;6:7821. DOI: 10.1038/ncomms8821
[13] Dhasarathy A, Phadke D, Mav D, Shah RR, Wade PA. The transcription factors Snail and 
Slug activate the transforming growth factor-beta signaling pathway in breast cancer. 
PLoS One. 2011;6:e26514. DOI: 10.1371/journal.pone.0026514
[14] Liu YN, Lee WW, Wang CY, Chao TH, Chen Y, Chen JH. Regulatory mechanisms con-
trolling human E-cadherin gene expression. Oncogene. 2005;24:8277-8290. DOI: 10.1038/
sj.onc.1208991
[15] Tuo H, Zheng X, Tu K, Zhou Z, Yao Y, Liu Q. Expression of PCAF in hepatocellular carci-
noma and its clinical significance. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2013;29:297-300
[16] Li Q, Liu Z, Xu M, Xue Y, Yao B, Dou C, et al. PCAF inhibits hepatocellular carcinoma 
metastasis by inhibition of epithelial-mesenchymal transition by targeting Gli-1. Cancer 
Letters. 2016;375:190-198. DOI: 10.1016/j.canlet.2016.02.053
[17] Wan J, Zhan J, Li S, Ma J, Xu W, Liu C, et al. PCAF-primed EZH2 acetylation regulates 
its stability and promotes lung adenocarcinoma progression. Nucleic Acids Research. 
2015;43:3591-3604. DOI: 10.1093/nar/gkv238
[18] Taipale M, Rea S, Richter K, Vilar A, Lichter P, Imhof A, et al. hMOF histone acetyltrans-
ferase is required for histone H4 lysine 16 acetylation in mammalian cells. Molecular and 
Cellular Biology. 2005;25:6798-6810. DOI: 10.1128/mcb.25.15.6798-6810.2005
[19] Luo H, Shenoy AK, Li X, Jin Y, Jin L, Cai Q, et al. MOF acetylates the histone demethylase 
LSD1 to suppress epithelial-to-mesenchymal transition. Cell Reports. 2016;15:2665-2678. 
DOI: 10.1016/j.celrep.2016.05.050
[20] Shi J, Wang Y, Zeng L, Wu Y, Deng J, Zhang Q, et al. Disrupting the interaction of BRD4 
with diacetylated Twist suppresses tumorigenesis in basal-like breast cancer. Cancer 
Cell. 2014;25:210-225. DOI: 10.1016/j.ccr.2014.01.028
[21] Ramakrishnan S, Ku S, Ciamporcero E, Miles KM, Attwood K, Chintala S, et al. HDAC 
1 and 6 modulate cell invasion and migration in clear cell renal cell carcinoma. BMC 
Cancer. 2016;16:617. DOI: 10.1186/s12885-016-2604-7
[22] von Burstin J, Eser S, Paul MC, Seidler B, Brandl M, Messer M, et al. E-cadherin regu-
lates metastasis of pancreatic cancer in vivo and is suppressed by a SNAIL/HDAC1/
HDAC2 repressor complex. Gastroenterology. 2009;137:361-71, 371.e1-5. DOI: 10.1053/j.
gastro.2009.04.004
[23] Peinado H, Ballestar E, Esteller M, Cano A. Snail mediates E-cadherin repression by the 
recruitment of the Sin3A/histone deacetylase 1 (HDAC1)/HDAC2 complex. Molecular 
and Cellular Biology. 2004;24:306-319
[24] Tripathi MK, Misra S, Khedkar SV, Hamilton N, Irvin-Wilson C, Sharan C, et al. Regulation 
of BRCA2 gene expression by the SLUG repressor protein in human breast cells. The 
Journal of Biological Chemistry. 2005;280:17163-17171. DOI: 10.1074/jbc.M501375200
Cancer Metastasis58
[25] Aghdassi A, Sendler M, Guenther A, Mayerle J, Behn CO, Heidecke CD, et al. Recruitment 
of histone deacetylases HDAC1 and HDAC2 by the transcriptional repressor ZEB1 
downregulates E-cadherin expression in pancreatic cancer. Gut. 2012;61:439-448. DOI: 
10.1136/gutjnl-2011-300,060
[26] Byles V, Zhu L, Lovaas JD, Chmilewski LK, Wang J, Faller DV, et al. SIRT1 induces EMT 
by cooperating with EMT transcription factors and enhances prostate cancer cell migra-
tion and metastasis. Oncogene. 2012;31:4619-4629. DOI: 10.1038/onc.2011.612
[27] Roche J, Nasarre P, Gemmill R, Baldys A, Pontis J, Korch C, et al. Global decrease of 
histone H3K27 acetylation in ZEB1-induced epithelial to mesenchymal transition in lung 
cancer cells. Cancers (Basel). 2013;5:334-356. DOI: 10.3390/cancers5020334
[28] He J, Shen S, Lu W, Zhou Y, Hou Y, Zhang Y, et al. HDAC1 promoted migration and inva-
sion binding with TCF12 by promoting EMT progress in gallbladder cancer. Oncotarget. 
2016;7:32754-32764. DOI: 10.18632/oncotarget.8740
[29] Ye Y, Xiao Y, Wang W, Yearsley K, Gao JX, Barsky SH. ERalpha suppresses slug expres-
sion directly by transcriptional repression. The Biochemical Journal. 2008;416:179-187. 
DOI: 10.1042/bj20080328
[30] Zhang X, Yuan Z, Zhang Y, Yong S, Salas-Burgos A, Koomen J, et al. HDAC6 modu-
lates cell motility by altering the acetylation level of cortactin. Molecular Cell. 2007;27: 
197-213. DOI: 10.1016/j.molcel.2007.05.033
[31] Gu S, Liu Y, Zhu B, Ding K, Yao TP, Chen F, et al. Loss of alpha-tubulin acetylation 
is associated with TGF-beta-induced epithelial-mesenchymal transition. The Journal of 
Biological Chemistry. 2016;291:5396-5405. DOI: 10.1074/jbc.M115.713123
[32] Dokmanovic M, Marks PA. Prospects: histone deacetylase inhibitors. Journal of Cellular 
Biochemistry. 2005;96:293-304. DOI: 10.1002/jcb.20532
[33] Eckschlager T, Plch J, Stiborova M, Hrabeta J. Histone deacetylase inhibitors as anticancer 
drugs. International Journal of Molecular Sciences. 2017;18. DOI: 10.3390/ijms18071414
[34] Trapani D, Esposito A, Criscitiello C, Mazzarella L, Locatelli M, Minchella I, et al. 
Entinostat for the treatment of breast cancer. Expert Opinion on Investigational Drugs. 
2017;26:965-971. DOI: 10.1080/13543784.2017.1353077
[35] Damaskos C, Garmpis N, Valsami S, Kontos M, Spartalis E, Kalampokas T, et al. Histone 
deacetylase inhibitors: An attractive therapeutic strategy against breast cancer. Anti-
cancer Research. 2017;37:35-46. DOI: 10.21873/anticanres.11286
[36] Tang HM, Kuay KT, Koh PF, Asad M, Tan TZ, Chung VY, et al. An epithelial marker 
promoter induction screen identifies histone deacetylase inhibitors to restore epithelial 
differentiation and abolishes anchorage independence growth in cancers. Cell Death 
Discovery. 2016;2:16041. DOI: 10.1038/cddiscovery.2016.41
[37] Meidhof S, Brabletz S, Lehmann W, Preca BT, Mock K, Ruh M, et al. ZEB1-associated 
drug resistance in cancer cells is reversed by the class I HDAC inhibitor mocetinostat. 
EMBO Molecular Medicine. 2015;7:831-847. DOI: 10.15252/emmm.201404396
The Landscape of Histone Modification in Cancer Metastasis
http://dx.doi.org/10.5772/intechopen.78383
59
[38] Kristensen LS, Nielsen HM, Hansen LL. Epigenetics and cancer treatment. European 
Journal of Pharmacology. 2009;625:131-142. DOI: 10.1016/j.ejphar.2009.10.011
[39] Jiang GM, Wang HS, Zhang F, Zhang KS, Liu ZC, Fang R, et al. Histone deacetylase 
inhibitor induction of epithelial-mesenchymal transitions via up-regulation of Snail 
facilitates cancer progression. Biochimica et Biophysica Acta. 2013;1833:663-671. DOI: 
10.1016/j.bbamcr.2012.12.002
[40] Kong D, Ahmad A, Bao B, Li Y, Banerjee S, Sarkar FH. Histone deacetylase inhibi-
tors induce epithelial-to-mesenchymal transition in prostate cancer cells. PLoS One. 
2012;7:e45045. DOI: 10.1371/journal.pone.0045045
[41] Pokholok DK, Harbison CT, Levine S, Cole M, Hannett NM, Lee TI, et al. Genome-wide 
map of nucleosome acetylation and methylation in yeast. Cell. 2005;122:517-527. DOI: 
10.1016/j.cell.2005.06.026
[42] Lachner M, Jenuwein T. The many faces of histone lysine methylation. Current Opinion 
in Cell Biology. 2002;14:286-298
[43] Zhu Y, Zhu MX, Zhang XD, Xu XE, Wu ZY, Liao LD, et al. SMYD3 stimulates EZR 
and LOXL2 transcription to enhance proliferation, migration, and invasion in esopha-
geal squamous cell carcinoma. Human Pathology. 2016;52:153-163. DOI: 10.1016/j.
humpath.2016.01.012.
[44] Liu Y, Liu H, Luo X, Deng J, Pan Y, Liang H. Overexpression of SMYD3 and matrix 
metalloproteinase-9 are associated with poor prognosis of patients with gastric cancer. 
Tumor Biology. 2015;36:4377-4386. DOI: 10.1007/s13277-015-3077-z
[45] Yu BD, Hess JL, Horning SE, Brown GA, Korsmeyer SJ. Altered Hox expression and 
segmental identity in Mll-mutant mice. Nature. 1995;378:505-508. DOI: 10.1038/378505a0
[46] Bhan A, Deb P, Shihabeddin N, Ansari KI, Brotto M, Mandal SS. Histone methylase 
MLL1 coordinates with HIF and regulate lncRNA HOTAIR expression under hypoxia. 
Gene. 2017;629:16-28. DOI: 10.1016/j.gene.2017.07.069
[47] Qiang R, Cai N, Wang X, Wang L, Cui K, Wang X, et al. MLL1 promotes cervical car-
cinoma cell tumorigenesis and metastasis through interaction with beta-catenin. Onco 
Targets and Therapy. 2016;9:6631-6640. DOI: 10.2147/ott.s114370
[48] Abudureheman A, Ainiwaer J, Hou Z, Niyaz M, Turghun A, Hasim A, et al. High MLL2 
expression predicts poor prognosis and promotes tumor progression by inducing 
EMT in esophageal squamous cell carcinoma. Journal of Cancer Research and Clinical 
Oncology. 2018. DOI: 10.1007/s00432-018-2625-5
[49] Xia M, Xu L, Leng Y, Gao F, Xia H, Zhang D, et al. Downregulation of MLL3 in esopha-
geal squamous cell carcinoma is required for the growth and metastasis of cancer cells. 
Tumor Biology. 2015;36:605-613. DOI: 10.1007/s13277-014-2616-3
[50] Kim JH, Sharma A, Dhar SS, Lee SH, Gu B, Chan CH, et al. UTX and MLL4 coordinately 
regulate transcriptional programs for cell proliferation and invasiveness in breast cancer 
cells. Cancer Research. 2014;74:1705-1717. DOI: 10.1158/0008-5472.can-13-1896
Cancer Metastasis60
[51] Lin Y, Wu Y, Li J, Dong C, Ye X, Chi YI, et al. The SNAG domain of Snail1 functions 
as a molecular hook for recruiting lysine-specific demethylase 1. The EMBO Journal. 
2010;29:1803-1816. DOI: 10.1038/emboj.2010.63
[52] Wu ZQ, Li XY, Hu CY, Ford M, Kleer CG, Weiss SJ. Canonical Wnt signaling regulates 
Slug activity and links epithelial-mesenchymal transition with epigenetic Breast Cancer 
1, Early Onset (BRCA1) repression. Proceedings of the National Academy of Sciences of 
the United States of America. 2012;109:16654-16659. DOI: 10.1073/pnas.1205822109
[53] Alsaqer SF, Tashkandi MM, Kartha VK, Yang YT, Alkheriji Y, Salama A, et al. Inhibition 
of LSD1 epigenetically attenuates oral cancer growth and metastasis. Oncotarget. 2017; 
8:73372-73,386. DOI: 10.18632/oncotarget.19637
[54] Feng T, Wang Y, Lang Y, Zhang Y. KDM5A promotes proliferation and EMT in ovar-
ian cancer and closely correlates with PTX resistance. Molecular Medicine Reports. 
2017;16:3573-3580. DOI: 10.3892/mmr.2017.6960
[55] Cao J, Liu Z, Cheung WK, Zhao M, Chen SY, Chan SW, et al. Histone demethylase RBP2 
is critical for breast cancer progression and metastasis. Cell Reports. 2014;6:868-877. 
DOI: 10.1016/j.celrep.2014.02.004
[56] Liang X, Zeng J, Wang L, Shen L, Ma X, Li S, et al. Histone demethylase RBP2 pro-
motes malignant progression of gastric cancer through TGF-beta1-(p-Smad3)-RBP2-
E-cadherin-Smad3 feedback circuit. Oncotarget. 2015;6:17661-17674. DOI: 10.18632/
oncotarget.3756
[57] Tang B, Qi G, Tang F, Yuan S, Wang Z, Liang X, et al. JARID1B promotes metastasis and 
epithelial-mesenchymal transition via PTEN/AKT signaling in hepatocellular carcinoma 
cells. Oncotarget. 2015;6:12723-12739. DOI: 10.18632/oncotarget.3713
[58] Wang Q, Wei J, Su P, Gao P. Histone demethylase JARID1C promotes breast cancer 
metastasis cells via down regulating BRMS1 expression. Biochemical and Biophysical 
Research Communications. 2015;464:659-666. DOI: 10.1016/j.bbrc.2015.07.049
[59] Wang L, Zehir A, Nafa K, Zhou N, Berger MF, Casanova J, et al. Genomic aberrations 
frequently alter chromatin regulatory genes in chordoma. Genes, Chromosomes and 
Cancer. 2016;55:591-600. DOI: 10.1002/gcc.22362
[60] Chen JY, Li CF, Chu PY, Lai YS, Chen CH, Jiang SS, et al. Lysine demethylase 2A pro-
motes stemness and angiogenesis of breast cancer by upregulating Jagged1. Oncotarget. 
2016;7:27689-27710. DOI: 10.18632/oncotarget.8381
[61] Wagner KW, Alam H, Dhar SS, Giri U, Li N, Wei Y, et al. KDM2A promotes lung 
tumorigenesis by epigenetically enhancing ERK1/2 signaling. The Journal of Clinical 
Investigation. 2013;123:5231-5246. DOI: 10.1172/jci68642
[62] Zhao Z, Sun C, Li F, Han J, Li X, Song Z. Overexpression of histone demethylase JMJD5 
promotes metastasis and indicates a poor prognosis in breast cancer. International 
Journal of Clinical and Experimental Pathology. 2015;8:10325-10334
[63] Nguyen AT, Zhang Y. The diverse functions of Dot1 and H3K79 methylation. Genes and 
Development. 2011;25:1345-1358. DOI: 10.1101/gad.2057811
The Landscape of Histone Modification in Cancer Metastasis
http://dx.doi.org/10.5772/intechopen.78383
61
[64] Daigle SR, Olhava EJ, Therkelsen CA, Majer CR, Sneeringer CJ, Song J, et al. Selective 
killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. 
Cancer Cell. 2011;20:53-65. DOI: 10.1016/j.ccr.2011.06.009
[65] Zhang L, Deng L, Chen F, Yao Y, Wu B, Wei L, et al. Inhibition of histone H3K79 meth-
ylation selectively inhibits proliferation, self-renewal and metastatic potential of breast 
cancer. Oncotarget. 2014;5:10665-10677. DOI: 10.18632/oncotarget.2496
[66] Bjorkman M, Ostling P, Harma V, Virtanen J, Mpindi JP, Rantala J, et al. Systematic 
knockdown of epigenetic enzymes identifies a novel histone demethylase PHF8 overex-
pressed in prostate cancer with an impact on cell proliferation, migration and invasion. 
Oncogene. 2012;31:3444-3456. DOI: 10.1038/onc.2011.512
[67] Li S, Sun A, Liang X, Ma L, Shen L, Li T, et al. Histone demethylase PHF8 promotes pro-
gression and metastasis of gastric cancer. American Journal of Cancer Research. 2017; 
7:448-461
[68] Tschiersch B, Hofmann A, Krauss V, Dorn R, Korge G, Reuter G. The protein encoded 
by the Drosophila position-effect variegation suppressor gene Su(var)3-9 combines 
domains of antagonistic regulators of homeotic gene complexes. The EMBO Journal. 
1994;13:3822-3831
[69] Shilatifard A. Molecular implementation and physiological roles for histone H3 lysine 
4 (H3K4) methylation. Current Opinion in Cell Biology. 2008;20:341-348. DOI: 10.1016/j.
ceb.2008.03.019
[70] Wen B, Wu H, Shinkai Y, Irizarry RA, Feinberg AP. Large histone H3 lysine 9 dimeth-
ylated chromatin blocks distinguish differentiated from embryonic stem cells. Nature 
Genetics. 2009;41:246-250. DOI: 10.1038/ng.297
[71] Dong C, Wu Y, Wang Y, Wang C, Kang T, Rychahou PG, et al. Interaction with Suv39H1 
is critical for Snail-mediated E-cadherin repression in breast cancer. Oncogene. 2013; 
32:1351-1362. DOI: 10.1038/onc.2012.169
[72] Dong C, Wu Y, Yao J, Wang Y, Yu Y, Rychahou PG, et al. G9a interacts with Snail and is 
critical for Snail-mediated E-cadherin repression in human breast cancer. The Journal of 
Clinical Investigation. 2012;122:1469-1486. DOI: 10.1172/jci57349
[73] Huang T, Zhang P, Li W, Zhao T, Zhang Z, Chen S, et al. G9A promotes tumor cell 
growth and invasion by silencing CASP1 in non-small-cell lung cancer cells. Cell Death 
and Disease. 2017;8:e2726. DOI: 10.1038/cddis.2017.65
[74] Chen MW, Hua KT, Kao HJ, Chi CC, Wei LH, Johansson G, et al. H3K9 histone meth-
yltransferase G9a promotes lung cancer invasion and metastasis by silencing the cell 
adhesion molecule Ep-CAM. Cancer Research. 2010;70:7830-7840. DOI: 10.1158/0008-
5472.can-10-0833
[75] Sun Y, Wei M, Ren SC, Chen R, Xu WD, Wang FB, et al. Histone methyltransferase 
SETDB1 is required for prostate cancer cell proliferation, migration and invasion. Asian 
Journal of Andrology. 2014;16:319-324. DOI: 10.4103/1008-682x.122812
Cancer Metastasis62
[76] Wong CM, Wei L, Law CT, Ho DW, Tsang FH, Au SL, et al. Up-regulation of histone 
methyltransferase SETDB1 by multiple mechanisms in hepatocellular carcinoma pro-
motes cancer metastasis. Hepatology. 2016;63:474-487. DOI: 10.1002/hep.28304
[77] Zhang H, Cai K, Wang J, Wang X, Cheng K, Shi F, et al. MiR-7, inhibited indirectly 
by lincRNA HOTAIR, directly inhibits SETDB1 and reverses the EMT of breast cancer 
stem cells by downregulating the STAT3 pathway. Stem Cells. 2014;32:2858-2868. DOI: 
10.1002/stem.1795
[78] Ramadoss S, Guo G, Wang CY. Lysine demethylase KDM3A regulates breast cancer cell 
invasion and apoptosis by targeting histone and the non-histone protein p53. Oncogene. 
2017;36:47-59. DOI: 10.1038/onc.2016.174
[79] Sechler M, Parrish JK, Birks DK, Jedlicka P. The histone demethylase KDM3A, and its 
downstream target MCAM, promote Ewing Sarcoma cell migration and metastasis. 
Oncogene. 2017;36:4150-4160. DOI: 10.1038/onc.2017.44
[80] Paolicchi E, Crea F, Farrar WL, Green JE, Danesi R. Histone lysine demethylases in 
breast cancer. Critical Reviews in Oncology/Hematology. 2013;86:97-103. DOI: 10.1016/j.
critrevonc.2012.11.008
[81] Liu Y, Zheng P, Liu Y, Ji T, Liu X, Yao S, et al. An epigenetic role for PRL-3 as a regu-
lator of H3K9 methylation in colorectal cancer. Gut. 2013;62:571-581. DOI: 10.1136/
gutjnl-2011-301,059
[82] Li LL, Xue AM, Li BX, Shen YW, Li YH, Luo CL, et al. Erratum to: JMJD2A contributes 
to breast cancer progression through transcriptional repression of the tumor suppressor 
ARHI. Breast Cancer Research. 2016;18:114. DOI: 10.1186/s13058-016-0776-3
[83] Zhao L, Li W, Zang W, Liu Z, Xu X, Yu H, et al. JMJD2B promotes epithelial-mesenchy-
mal transition by cooperating with beta-catenin and enhances gastric cancer metastasis. 
Clinical Cancer Research. 2013;19:6419-6429. DOI: 10.1158/1078-0432.ccr-13-0254
[84] Luo W, Chang R, Zhong J, Pandey A, Semenza GL. Histone demethylase JMJD2C is 
a coactivator for hypoxia-inducible factor 1 that is required for breast cancer progres-
sion. Proceedings of the National Academy of Sciences of the United States of America. 
2012;109:E3367-E3376. DOI: 10.1073/pnas.1217394109
[85] Yokoyama Y, Matsumoto A, Hieda M, Shinchi Y, Ogihara E, Hamada M, et al. Loss of 
histone H4K20 trimethylation predicts poor prognosis in breast cancer and is associated 
with invasive activity. Breast Cancer Research. 2014;16:R66. DOI: 10.1186/bcr3681
[86] Viotti M, Wilson C, McCleland M, Koeppen H, Haley B, Jhunjhunwala S, et al. SUV420H2 
is an epigenetic regulator of epithelial/mesenchymal states in pancreatic cancer. The 
Journal of Cell Biology. 2018;217:763-777. DOI: 10.1083/jcb.201705031
[87] Fang J, Feng Q, Ketel CS, Wang H, Cao R, Xia L, et al. Purification and functional char-
acterization of SET8, a nucleosomal histone H4-lysine 20-specific methyltransferase. 
Current Biology. 2002;12:1086-1099
The Landscape of Histone Modification in Cancer Metastasis
http://dx.doi.org/10.5772/intechopen.78383
63
[88] Yang F, Sun L, Li Q, Han X, Lei L, Zhang H, et al. SET8 promotes epithelial-mesenchy-
mal transition and confers TWIST dual transcriptional activities. The EMBO Journal. 
2012;31:110-123. DOI: 10.1038/emboj.2011.364
[89] Hou L, Li Q, Yu Y, Li M, Zhang D. SET8 induces epithelialmesenchymal transition 
and enhances prostate cancer cell metastasis by cooperating with ZEB1. Molecular 
Medicine Reports. 2016;13:1681-1688. DOI: 10.3892/mmr.2015.4733
[90] Della Corte CM, Bellevicine C, Vicidomini G, Vitagliano D, Malapelle U, Accardo M, 
et al. SMO gene amplification and activation of the Hedgehog pathway as novel mecha-
nisms of resistance to anti-epidermal growth factor receptor drugs in human lung can-
cer. Clinical Cancer Research. 2015;21:4686-4697. DOI: 10.1158/1078-0432.ccr-14-3319
[91] Fu L, Wu H, Cheng SY, Gao D, Zhang L, Zhao Y. Set7 mediated Gli3 methylation plays 
a positive role in the activation of Sonic Hedgehog pathway in mammals. eLife. 2016;5. 
DOI: 10.7554/eLife.15690
[92] Bernstein BE, Meissner A, Lander ES. The mammalian epigenome. Cell. 2007;128:669-681. 
DOI: 10.1016/j.cell.2007.01.033
[93] Barski A, Cuddapah S, Cui K, Roh TY, Schones DE, Wang Z, et al. High-resolution 
profiling of histone methylations in the human genome. Cell. 2007;129:823-837. DOI: 
10.1016/j.cell.2007.05.009
[94] Hublitz P, Albert M, Peters AH. Mechanisms of transcriptional repression by histone 
lysine methylation. The International Journal of Developmental Biology. 2009;53:335-354. 
DOI: 10.1387/ijdb.082717 ph
[95] Xiang Y, Zhu Z, Han G, Lin H, Xu L, Chen CD. JMJD3 is a histone H3K27 demethylase. 
Cell Research. 2007;17:850-857. DOI: 10.1038/cr.2007.83
[96] Tiwari N, Tiwari VK, Waldmeier L, Balwierz PJ, Arnold P, Pachkov M, et al. Sox4 is a mas-
ter regulator of epithelial-mesenchymal transition by controlling Ezh2 expression and 
epigenetic reprogramming. Cancer Cell. 2013;23:768-783. DOI: 10.1016/j.ccr.2013.04.020
[97] Chien YC, Liu LC, Ye HY, Wu JY, Yu YL. EZH2 promotes migration and invasion of 
triple-negative breast cancer cells via regulating TIMP2-MMP-2/−9 pathway. American 
Journal of Cancer Research. 2018;8:422-434
[98] Herranz N, Pasini D, Diaz VM, Franci C, Gutierrez A, Dave N, et al. Polycomb complex 
2 is required for E-cadherin repression by the Snail1 transcription factor. Molecular and 
Cellular Biology. 2008;28:4772-4781. DOI: 10.1128/MCB.00323-08
[99] Zha L, Cao Q, Cui X, Li F, Liang H, Xue B, et al. Epigenetic regulation of E-cadherin 
expression by the histone demethylase UTX in colon cancer cells. Medical Oncology. 
2016;33:21. DOI: 10.1007/s12032-016-0734-z
[100] Choi HJ, Park JH, Park M, Won HY, Joo HS, Lee CH, et al. UTX inhibits EMT-induced 
breast CSC properties by epigenetic repression of EMT genes in cooperation with LSD1 
and HDAC1. EMBO Reports. 2015;16:1288-1298. DOI: 10.15252/embr.201540244
Cancer Metastasis64
[101] Tang B, Qi G, Tang F, Yuan S, Wang Z, Liang X, et al. Aberrant JMJD3 expression upreg-
ulates slug to promote migration, invasion, and stem cell-like behaviors in hepatocellu-
lar carcinoma. Cancer Research. 2016;76:6520-6532. DOI: 10.1158/0008-5472.can-15-3029
[102] Park WY, Hong BJ, Lee J, Choi C, Kim MY. H3K27 demethylase JMJD3 employs the 
NF-kappaB and BMP signaling pathways to modulate the tumor microenvironment 
and promote melanoma progression and metastasis. Cancer Research. 2016;76:161-170. 
DOI: 10.1158/0008-5472.can-15-0536
[103] Gao Y, Zhao Y, Zhang J, Lu Y, Liu X, Geng P, et al. The dual function of PRMT1 in mod-
ulating epithelial-mesenchymal transition and cellular senescence in breast cancer cells 
through regulation of ZEB1. Scientific Reports. 2016;6:19874. DOI: 10.1038/srep19874
[104] Avasarala S, Van Scoyk M, Karuppusamy Rathinam MK, Zerayesus S, Zhao X, Zhang W, 
et al. PRMT1 is a novel regulator of epithelial-mesenchymal-transition in non-small cell 
lung cancer. The Journal of Biological Chemistry. 2015;290:13479-13489. DOI: 10.1074/ 
jbc.M114.636050
[105] Li L, Zhang Z, Ma T, Huo R. PRMT1 regulates tumor growth and metastasis of human 
melanoma via targeting ALCAM. Molecular Medicine Reports. 2016;14:521-528. DOI: 
10.3892/mmr.2016.5273
[106] Gou Q, He S, Zhou Z. Protein arginine N-methyltransferase 1 promotes the prolif-
eration and metastasis of hepatocellular carcinoma cells. Tumor Biology. 2017;39. DOI: 
10.1177/1010428317691419
[107] Zhou W, Yue H, Li C, Chen H, Yuan Y. Protein arginine methyltransferase 1 promoted 
the growth and migration of cancer cells in esophageal squamous cell carcinoma. 
Tumor Biology. 2016;37:2613-2619. DOI: 10.1007/s13277-015-4098-3
[108] Goulet I, Gauvin G, Boisvenue S, Cote J. Alternative splicing yields protein arginine 
methyltransferase 1 isoforms with distinct activity, substrate specificity, and subcel-
lular localization. The Journal of Biological Chemistry. 2007;282:33009-33021. DOI: 
10.1074/jbc.M704349200
[109] Bondy-Chorney E, Baldwin RM, Didillon A, Chabot B, Jasmin BJ, Cote J. RNA bind-
ing protein RALY promotes protein arginine methyltransferase 1 alternatively spliced 
isoform v2 relative expression and metastatic potential in breast cancer cells. The 
International Journal of Biochemistry and Cell Biology. 2017;91:124-135. DOI: 10.1016/j.
biocel.2017.07.008
[110] Zhong J, Cao RX, Hong T, Yang J, Zu XY, Xiao XH, et al. Identification and expres-
sion analysis of a novel transcript of the human PRMT2 gene resulted from alternative 
polyadenylation in breast cancer. Gene. 2011;487:1-9. DOI: 10.1016/j.gene.2011.06.022
[111] Qi C, Chang J, Zhu Y, Yeldandi AV, Rao SM, Zhu YJ. Identification of protein argi-
nine methyltransferase 2 as a coactivator for estrogen receptor alpha. The Journal of 
Biological Chemistry. 2002;277. DOI: 28624-30. DOI: 10.1074/jbc.M201053200
The Landscape of Histone Modification in Cancer Metastasis
http://dx.doi.org/10.5772/intechopen.78383
65
[112] Zhong J, Cao RX, Zu XY, Hong T, Yang J, Liu L, et al. Identification and characterization of 
novel spliced variants of PRMT2 in breast carcinoma. The FEBS Journal. 2012;279:316-335. 
DOI: 10.1111/j.1742-4658.2011.08426.x
[113] Wang L, Zhao Z, Meyer MB, Saha S, Yu M, Guo A, et al. CARM1 methylates chromatin 
remodeling factor BAF155 to enhance tumor progression and metastasis. Cancer Cell. 
2014;25:21-36. DOI: 10.1016/j.ccr.2013.12.007
[114] Habashy HO, Rakha EA, Ellis IO, Powe DG. The estrogen receptor coactivator CARM1 
has an oncogenic effect and is associated with poor prognosis in breast cancer. Breast 
Cancer Research and Treatment. 2013;140:307-316. DOI: 10.1007/s10549-013-2614-y
[115] Ohkura N, Takahashi M, Yaguchi H, Nagamura Y, Tsukada T. Coactivator-associated 
arginine methyltransferase 1, CARM1, affects pre-mRNA splicing in an isoform-spe-
cific manner. The Journal of Biological Chemistry. 2005;280:28927-28935. DOI: 10.1074/
jbc.M502173200
[116] Fu T, Lv X, Kong Q, Yuan C. A novel SHARPIN-PRMT5-H3R2me1 axis is essential 
for lung cancer cell invasion. Oncotarget. 2017;8:54809-54820. DOI: 10.18632/onco- 
target.18957
[117] Tsutsui T, Fukasawa R, Shinmyouzu K, Nakagawa R, Tobe K, Tanaka A, et al. Mediator 
complex recruits epigenetic regulators via its two cyclin-dependent kinase subunits to 
repress transcription of immune response genes. The Journal of Biological Chemistry. 
2013;288:20955-20965. DOI: 10.1074/jbc.M113.486746
[118] Migliori V, Muller J, Phalke S, Low D, Bezzi M, Mok WC, et al. Symmetric dimethylation 
of H3R2 is a newly identified histone mark that supports euchromatin maintenance. 
Nature Structural and Molecular Biology. 2012;19:136-144. DOI: 10.1038/nsmb.2209
[119] Chen H, Lorton B, Gupta V, Shechter D. A TGFbeta-PRMT5-MEP50 axis regulates can-
cer cell invasion through histone H3 and H4 arginine methylation coupled transcrip-
tional activation and repression. Oncogene. 2017;36:373-386. DOI: 10.1038/onc.2016.205
[120] Hou Z, Peng H, Ayyanathan K, Yan KP, Langer EM, Longmore GD, et al. The LIM protein 
AJUBA recruits protein arginine methyltransferase 5 to mediate SNAIL-dependent tran-
scriptional repression. Molecular and Cellular Biology. 2008;28:3198-3207. DOI: 10.1128/ 
mcb.01435-07
[121] Hu D, Gur M, Zhou Z, Gamper A, Hung MC, Fujita N, et al. Interplay between arginine 
methylation and ubiquitylation regulates KLF4-mediated genome stability and carci-
nogenesis. Nature Communications. 2015;6:8419. DOI: 10.1038/ncomms9419
[122] Yoshimatsu M, Toyokawa G, Hayami S, Unoki M, Tsunoda T, Field HI, et al. Dysre-
gulation of PRMT1 and PRMT6, Type I arginine methyltransferases, is involved in vari-
ous types of human cancers. International Journal of Cancer. 2011;128:562-573. DOI: 
10.1002/ijc.25366
[123] Dowhan DH, Harrison MJ, Eriksson NA, Bailey P, Pearen MA, Fuller PJ, et al. Protein 
arginine methyltransferase 6-dependent gene expression and splicing: association with 
Cancer Metastasis66
breast cancer outcomes. Endocrine-Related Cancer. 2012;19:509-526. DOI: 10.1530/
erc-12-0100
[124] Geng P, Zhang Y, Liu X, Zhang N, Liu Y, Liu X, et al. Automethylation of protein 
arginine methyltransferase 7 and its impact on breast cancer progression. The FASEB 
Journal. 2017;31:2287-2300. DOI: 10.1096/fj.201601196R
[125] Baldwin RM, Haghandish N, Daneshmand M, Amin S, Paris G, Falls TJ, et al. Protein 
arginine methyltransferase 7 promotes breast cancer cell invasion through the induc-
tion of MMP9 expression. Oncotarget. 2015;6:3013-3032. DOI: 10.18632/oncotarget.3072
[126] Thomassen M, Tan Q, Kruse TA. Gene expression meta-analysis identifies chromo-
somal regions and candidate genes involved in breast cancer metastasis. Breast Cancer 
Research and Treatment. 2009;113:239-249. DOI: 10.1007/s10549-008-9927-2
[127] Yang Y, Hadjikyriacou A, Xia Z, Gayatri S, Kim D, Zurita-Lopez C, et al. PRMT9 is 
a type II methyltransferase that methylates the splicing factor SAP145. Nature Com-
munications. 2015;6:6428. DOI: 10.1038/ncomms7428
[128] Jiang H, Zhou Z, Jin S, Xu K, Zhang H, Xu J, et al. PRMT9 promotes hepatocellular 
carcinoma invasion and metastasis via activating PI3K/Akt/GSK-3beta/Snail signaling. 
Cancer Science. 2018. DOI: 10.1111/cas.13598
[129] Greiner D, Bonaldi T, Eskeland R, Roemer E, Imhof A. Identification of a specific inhibitor 
of the histone methyltransferase SU(VAR)3-9. Nature Chemical Biology. 2005;1:143-145. 
DOI: 10.1038/nchembio721
[130] Lakshmikuttyamma A, Scott SA, DeCoteau JF, Geyer CR. Reexpression of epigenetically 
silenced AML tumor suppressor genes by SUV39H1 inhibition. Oncogene. 2010;29:576-588. 
DOI: 10.1038/onc.2009.361
[131] Kubicek S, O’Sullivan RJ, August EM, Hickey ER, Zhang Q, Teodoro ML, et al. Reversal 
of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase. 
Molecular Cell. 2007;25:473-481. DOI: 10.1016/j.molcel.2007.01.017
[132] Liu S, Ye D, Guo W, Yu W, He Y, Hu J, et al. G9a is essential for EMT-mediated metasta-
sis and maintenance of cancer stem cell-like characters in head and neck squamous cell 
carcinoma. Oncotarget. 2015;6:6887-6901. DOI: 10.18632/oncotarget.3159
[133] Vedadi M, Barsyte-Lovejoy D, Liu F, Rival-Gervier S, Allali-Hassani A, Labrie V, et al. 
A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells. 
Nature Chemical Biology. 2011;7:566-574. DOI: 10.1038/nchembio.599
[134] Liu XR, Zhou LH, Hu JX, Liu LM, Wan HP, Zhang XQ. UNC0638, a G9a inhibitor, 
suppresses epithelialmesenchymal transitionmediated cellular migration and invasion 
in triple negative breast cancer. Molecular Medicine Reports. 2018;17:2239-2244. DOI: 
10.3892/mmr.2017.8190
[135] Finley A, Copeland RA. Small molecule control of chromatin remodeling. Chemistry 
and Biology. 2014;21:1196-1210. DOI: 10.1016/j.chembiol.2014.07.024
The Landscape of Histone Modification in Cancer Metastasis
http://dx.doi.org/10.5772/intechopen.78383
67
[136] Tan J, Yang X, Zhuang L, Jiang X, Chen W, Lee PL, et al. Pharmacologic disruption of 
Polycomb-repressive complex 2-mediated gene repression selectively induces apopto-
sis in cancer cells. Genes and Development. 2007;21:1050-1063. DOI: 10.1101/gad. 
1524107
[137] Mody HR, Hung SW, AlSaggar M, Griffin J, Govindarajan R. Inhibition of S-adenosylmethio-
nine-dependent methyltransferase attenuates TGFbeta1-induced EMT and metastasis in 
pancreatic cancer: Putative roles of miR-663a and miR-4787-5p. Molecular Cancer Research. 
2016;14:1124-1135. DOI: 10.1158/1541-7786.mcr-16-0083
[138] Wang L, Chang J, Varghese D, Dellinger M, Kumar S, Best AM, et al. A small molecule 
modulates Jumonji histone demethylase activity and selectively inhibits cancer growth. 
Nature Communications. 2013;4:2035. DOI: 10.1038/ncomms3035
[139] Cheng D, Yadav N, King RW, Swanson MS, Weinstein EJ, Bedford MT. Small molecule 
regulators of protein arginine methyltransferases. The Journal of Biological Chemistry. 
2004;279:23892-23899. DOI: 10.1074/jbc.M401853200
[140] Castellano S, Milite C, Ragno R, Simeoni S, Mai A, Limongelli V, et al. Design, synthesis 
and biological evaluation of carboxy analogues of arginine methyltransferase inhibitor 
1 (AMI-1). ChemMedChem. 2010;5:398-414. DOI: 10.1002/cmdc.200900459
[141] Zhang B, Dong S, Zhu R, Hu C, Hou J, Li Y, et al. Targeting protein arginine methyl-
transferase 5 inhibits colorectal cancer growth by decreasing arginine methylation of 
eIF4E and FGFR3. Oncotarget. 2015;6:22799-22811. DOI: 10.18632/oncotarget.4332
[142] Liu Z, Wang P, Chen H, Wold EA, Tian B, Brasier AR, et al. Drug discovery targeting 
bromodomain-containing protein 4. Journal of Medicinal Chemistry. 2017;60:4533-4558. 
DOI: 10.1021/acs.jmedchem.6b01761
[143] Fontanals-Cirera B, Hasson D, Vardabasso C, Di Micco R, Agrawal P, Chowdhury A, 
et al. Harnessing BET inhibitor sensitivity reveals AMIGO2 as a melanoma survival 
gene. Molecular Cell. 2017;68:731-744.e9. DOI: 10.1016/j.molcel.2017.11.004
[144] Wagner T, Robaa D, Sippl W, Jung M. Mind the methyl: methyllysine binding proteins in 
epigenetic regulation. ChemMedChem. 2014;9:466-483. DOI: 10.1002/cmdc.201300422
[145] Maison C, Almouzni G. HP1 and the dynamics of heterochromatin maintenance. 
Nature Reviews. Molecular Cell Biology. 2004;5:296-304. DOI: 10.1038/nrm1355
[146] Millanes-Romero A, Herranz N, Perrera V, Iturbide A, Loubat-Casanovas J, Gil J, et al. 
Regulation of heterochromatin transcription by Snail1/LOXL2 during epithelial-to-mes-
enchymal transition. Molecular Cell. 2013;52:746-757. DOI: 10.1016/j.molcel.2013.10.015
[147] Tang M, Shen H, Jin Y, Lin T, Cai Q, Pinard MA, et al. The malignant brain tumor (MBT) 
domain protein SFMBT1 is an integral histone reader subunit of the LSD1 demethyl-
ase complex for chromatin association and epithelial-to-mesenchymal transition. The 
Journal of Biological Chemistry. 2013;288:27680-27691. DOI: 10.1074/jbc.M113.482349
Cancer Metastasis68
[148] Wysocka J, Swigut T, Milne TA, Dou Y, Zhang X, Burlingame AL, et al. WDR5 asso-
ciates with histone H3 methylated at K4 and is essential for H3 K4 methylation and 
vertebrate development. Cell. 2005;121:859-872. DOI: 10.1016/j.cell.2005.03.036
[149] Wu MZ, Tsai YP, Yang MH, Huang CH, Chang SY, Chang CC, et al. Interplay between 
HDAC3 and WDR5 is essential for hypoxia-induced epithelial-mesenchymal transi-
tion. Molecular Cell. 2011;43:811-822. DOI: 10.1016/j.molcel.2011.07.012
[150] Margueron R, Justin N, Ohno K, Sharpe ML, Son J, Drury WJ 3rd, et al. Role of the 
polycomb protein EED in the propagation of repressive histone marks. Nature. 2009; 
461:762-767. DOI: 10.1038/nature08398
[151] Collins RE, Northrop JP, Horton JR, Lee DY, Zhang X, Stallcup MR, et al. The ankyrin 
repeats of G9a and GLP histone methyltransferases are mono- and dimethyllysine 
binding modules. Nature Structural and Molecular Biology. 2008;15:245-250. DOI: 
10.1038/nsmb.1384
[152] James LI, Barsyte-Lovejoy D, Zhong N, Krichevsky L, Korboukh VK, Herold JM, et al. 
Discovery of a chemical probe for the L3MBTL3 methyllysine reader domain. Nature 
Chemical Biology. 2013;9:184-191. DOI: 10.1038/nchembio.1157
[153] Stuckey JI, Dickson BM, Cheng N, Liu Y, Norris JL, Cholensky SH, et al. A cellular 
chemical probe targeting the chromodomains of Polycomb repressive complex 1. 
Nature Chemical Biology. 2016;12:180-187. DOI: 10.1038/nchembio.2007
[154] Shi Y, Sawada J, Sui G, Affar el B, Whetstine JR, Lan F, et al. Coordinated histone modi-
fications mediated by a CtBP co-repressor complex. Nature. 2003;422:735-738. DOI: 
10.1038/nature01550
[155] Shi Y, Lan F, Matson C, Mulligan P, Whetstine JR, Cole PA, et al. Histone demethylation 
mediated by the nuclear amine oxidase homolog LSD1. Cell. 2004;119:941-953. DOI: 
10.1016/j.cell.2004.12.012
[156] Nishioka K, Chuikov S, Sarma K, Erdjument-Bromage H, Allis CD, Tempst P, et al. Set9, 
a novel histone H3 methyltransferase that facilitates transcription by precluding histone 
tail modifications required for heterochromatin formation. Genes and Development. 
2002;16:479-489. DOI: 10.1101/gad.967202
[157] Wang H, Cao R, Xia L, Erdjument-Bromage H, Borchers C, Tempst P, et al. Purification 
and functional characterization of a histone H3-lysine 4-specific methyltransferase. 
Molecular Cell. 2001;8:1207-1217
[158] Fu J, Qin L, He T, Qin J, Hong J, Wong J, et al. The TWIST/Mi2/NuRD protein complex 
and its essential role in cancer metastasis. Cell Research. 2011;21:275-289. DOI: 10.1038/
cr.2010.118
[159] Chang Y, Sun L, Kokura K, Horton JR, Fukuda M, Espejo A, et al. MPP8 mediates the 
interactions between DNA methyltransferase Dnmt3a and H3K9 methyltransferase 
GLP/G9a. Nature Communications. 2011;2:533. DOI: 10.1038/ncomms1549
The Landscape of Histone Modification in Cancer Metastasis
http://dx.doi.org/10.5772/intechopen.78383
69
[160] Kokura K, Sun L, Bedford MT, Fang J. Methyl-H3K9-binding protein MPP8 mediates 
E-cadherin gene silencing and promotes tumor cell motility and invasion. The EMBO 
Journal. 2010;29:3673-3687. DOI: 10.1038/emboj.2010.239
[161] Sun L, Kokura K, Izumi V, Koomen JM, Seto E, Chen J, et al. MPP8 and SIRT1 crosstalk 
in E-cadherin gene silencing and epithelial-mesenchymal transition. EMBO Reports. 
2015;16:689-699. DOI: 10.15252/embr.201439792
Cancer Metastasis70
